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Abstract
EGF receptor activation requires both ligand-binding and receptor-mediated dimerization through receptor
domain II. The relationship between these processes, however, remains unclear. We have decoupled these
processes to examine the ligand-binding affinity and the structure of constitutively-monomeric and -dimeric
forms of the EGF receptor, as well as EGF receptor that dimerizes upon ligand-binding. Surprisingly,
monomeric receptor binds to the ligands EGF and TGFα with an affinity equivalent to that of dimerizing
receptor but with a unique binding enthalpy. This shows that monomeric, ligated EGF receptor adopts a state
that is distinct from that of EGF receptor within a homodimer, and this state may be relevant to heterodimeric
ErbB signaling complexes. Constitutively-dimerized receptor binds ligand with elevated affinity; however, it
still requires ligand to form the receptor domain II dimeric interface. In the absence of ligand, no ordered,
receptor domain II-mediated dimer interface is formed. Thus, the affinity effect does not arise from any pre-
organization or stabilization of the ligand-binding sites on the receptor, but rather through an entropic effect
of enforcing dimerization. Thus, pre-formed human receptor dimers require allosteric activation by ligand in
order to signal, and this allosteric mechanism is distinct from that we recently observed for the D.
melanogaster EGF receptor. Our observations on the allosteric mechanism of EGF receptor activation
prompted us to ask whether other EGF receptor ligands may exert unique allosteric effects. To this end, we
investigated the allosteric effects of the ligands Amphiregulin, Epiregulin, and Epigen on EGF receptor. We
report that Epiregulin and Epigen, in particular, exert unique allosteric regulation on the receptor, as
evidenced by divergent effects of EGFR variants on ligand-binding. Finally, we have studied ligand-binding
and dimerization of receptors bearing activating extracellular mutations that cause glioblastoma. We report
that these mutations elevate ligand-binding affinity, but they do not drive receptor dimerization. Our findings
inform a revised model of ligand-induced receptor activation, in which the dimerization interface is highly
sensitive to the presence and the identity of the bound ligand, and the domain I/domain II interface plays a
crucial auto-inhibitory role.
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ABSTRACT 
 
NOVEL INSIGHTS INTO THE ALLOSTERIC ACTIVATION OF THE EPIDERMAL GROWTH 
FACTOR RECEPTOR 
Nicholas J. Bessman 
Mark A. Lemmon 
EGF receptor activation requires both ligand-binding and receptor-mediated dimerization through 
receptor domain II.  The relationship between these processes, however, remains unclear.  We 
have decoupled these processes to examine the ligand-binding affinity and the structure of 
constitutively-monomeric and -dimeric forms of the EGF receptor, as well as EGF receptor that 
dimerizes upon ligand-binding.  Surprisingly, monomeric receptor binds to the ligands EGF and 
TGFα with an affinity equivalent to that of dimerizing receptor but with a unique binding enthalpy.  
This shows that monomeric, ligated EGF receptor adopts a state that is distinct from that of EGF 
receptor within a homodimer, and this state may be relevant to heterodimeric ErbB signaling 
complexes.  Constitutively-dimerized receptor binds ligand with elevated affinity; however, it still 
requires ligand to form the receptor domain II dimeric interface.  In the absence of ligand, no 
ordered, receptor domain II-mediated dimer interface is formed.  Thus, the affinity effect does not 
arise from any pre-organization or stabilization of the ligand-binding sites on the receptor, but 
rather through an entropic effect of enforcing dimerization.  Thus, pre-formed human receptor 
dimers require allosteric activation by ligand in order to signal, and this allosteric mechanism is 
distinct from that we recently observed for the D. melanogaster EGF receptor.   Our observations 
on the allosteric mechanism of EGF receptor activation prompted us to ask whether other EGF 
receptor ligands may exert unique allosteric effects.  To this end, we investigated the allosteric 
effects of the ligands Amphiregulin, Epiregulin, and Epigen on EGF receptor.  We report that 
Epiregulin and Epigen, in particular, exert unique allosteric regulation on the receptor, as 
evidenced by divergent effects of EGFR variants on ligand-binding.  Finally, we have studied 
ligand-binding and dimerization of receptors bearing activating extracellular mutations that cause 
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glioblastoma.  We report that these mutations elevate ligand-binding affinity, but they do not drive 
receptor dimerization.  Our findings inform a revised model of ligand-induced receptor activation, 
in which the dimerization interface is highly sensitive to the presence and the identity of the bound 
ligand, and the domain I/domain II interface plays a crucial auto-inhibitory role. 
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Chapter 1: EGF receptor signaling, from organismal biology to atomic resolution 
  
2 
 
Receptor tyrosine kinases: a conserved transmembrane signaling module  
 
Receptor tyrosine kinases, or RTKs, are a conserved family of transmembrane signaling proteins 
in metazoan organisms.  RTKs play a central role in organismal development and patterning.  
Beyond development, RTKs serve to maintain physiological homeostasis in mature organisms.  
Many of the earliest biochemical paradigms in physiology and development were, many decades 
later, found to depend directly upon the transmembrane signaling properties of RTKs.  For 
example, insulin was initially purified in the early 1920s by Frederick Banting and colleagues, and 
it was immediately shown to cure diabetes when injected at regular intervals(Banting, 1922).  
Later, Rita Levi-Montalcini and Stanley Cohen, working in close proximity in the 1950s, 
discovered two molecules with remarkable stimulatory effects on nerve cells and mouse 
development, respectively(Cohen, 1962; Levi-Montalcini, 1960).  These two molecules were 
termed ‘growth factors’.  With the advent of recombinant DNA technology and gene cloning in the 
1970s and 1980s, it was recognized that the receptors mediating the biological effects of insulin 
and other growth factors constitute just a handful of examples from a broad and conserved family 
of RTKs.  Each RTK senses a unique set of extracellular ligand molecules and transmits a signal 
to the interior of the cell by a broadly conserved enzymatic mechanism (Fig. 1).  Accordingly, 
RTKs broadly allow individual cells within a multi-cellular organism to respond appropriately to 
diverse developmental, physiological, and environmental cues, by exploiting a modular 
molecular- and network-architecture. 
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Figure 1: RTKs share a common architecture.  In the extracellular regions (orange), a wide 
variety of protein domains are present.  Ligand binds to these extracellular regions.  Each RTK 
sub-family binds a defined set of ligands, defined by the receptor extracellular regions.  A single-
pass, α-helical transmembrane domain connects the extracellular regions to a short 
juxtamembrane region, followed by a tyrosine kinase domain.  A variable-length, unstructured C-
tail region, rich in substrate tyrosines, lies at the C-terminus of the receptor protein. 
 
Biological roles 
Because the diversity of the RTK family resides primarily in the extracellular ligand-sensing 
machinery, RTKs are divided into sub-families based on these extracellular regions(Lemmon & 
Schlessinger, 2010).  Within each human RTK sub-family, there may be as few as one family 
member, or as many as fourteen.  In total, humans express 58 different RTKs, divided into 20 
sub-families.  Recent bioinformatic analyses have suggested an even broader family of RTKs is 
expressed in unicellular organisms, but the relevance of these to metazoan RTKs is unclear 
(Miller, 2012).  For the different metazoan species, the number of family members within each 
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sub-family correlates roughly with the complexity of the body plan and organism size.  For 
example, C. elegans and D. melanogaster express only one ErbB sub-family receptor, whereas 
mammals express four(Stein & Staros, 2006).  Similarly, humans express four fibroblast growth 
factor (FGF) receptors and 22 different FGF ligand molecules, where C. elegans expresses just 
two FGF ligands and one FGF receptor(Itoh, 2007).  In light of this observation, it is not surprising 
that RTKs seem to function primarily as master regulators of tissue development. 
 Each RTK sub-family is generally associated with the development of a particular subset 
of tissues or cell types.  Diversity within RTK sub-families adds another layer of regulation and 
complexity.  In the well-studied insulin receptor family of RTKs, genetic ablation of the signaling 
pathway universally results in growth retardation, although the magnitude and mechanism of the 
effect depends on the specific receptor or ligand targeted.  In mammals, knockout of the IGF-1 
growth factor (which stimulates the IGF-1 receptor) results in decreased bone cell proliferation 
and a severe growth retardation, whereas insulin receptor (IR) knockout results in a mild growth 
retardation, due to a slight decrease in adipose tissue mass – with no effect on early bone 
development(Nakae et al, 2001).  Similarly, within the mammalian PDGF receptor family, receptor 
deletion results in severe developmental defects and embryonic or early post-natal death due to 
insufficient numbers of specific smooth muscle cell populations in the vasculature.  Mice null for 
PDGF-A (a PDGFRα ligand) lack a population of smooth muscle cells that normally participates 
in formation of lung alveoli, and these mice display an emphysema-like phenotype at birth.  For 
PDGF-B (a PDGFRβ ligand), knockout results in embryonic death due to massive 
hemorrhaging(Betsholtz, 2004).  Hemorrhaging occurs because PDGF-B is required for the 
expansion of a vascular smooth muscle cell population that forms the primary wall structure of 
blood vessels.  In yet another illustration of this theme, Trk receptor family members are required 
for development of different neural tissues; TrkA for nociceptive sensory neurons (TrkA-null mice 
are insensitive to pain), and TrkB for the vestibular ganglion (TrkB-null mice exhibit defects in 
balance and locomotion)(Tessarollo, 1998).  It is clear that RTKs play a nearly ubiquitous role in 
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cellular differentiation and proliferation events underlying development, following a prototypical 
axis in which ligand and receptor act as an autonomous, modular signaling unit. 
In contrast to the well-defined and autonomous pathways described above, it must be noted that 
several RTKs require other accessory proteins, co-receptors, or higher-order oligomerization 
(beyond dimerization) in order to transmit their signals.  For example, the highly-conserved kinase 
activity within the intracellular domain of RTKs is severely compromised or absent in 8 out of the 
58 human RTKs: Ryk, Ror1, Ror2, ErbB3, CCK4, EphA10, EphB6, and SuRTK106(Mendrola et 
al, 2013; Shi et al, 2010).  For ErbB3 and EphB6 in particular, there is good evidence that these 
receptors can interact with other autonomous RTKs to modulate signaling, perhaps by activating 
them allosterically (Citri, 2003; Truitt & Freywald, 2011).  Furthermore, accumulating evidence 
suggests that several RTKs function as Wnt receptors or co-receptors.  To date, the RTKs MuSK, 
CCK4, Ryk, and Ror2 have been implicated in Wnt signaling(Niehrs, 2012).  Finally, higher-order 
oligomerization is known to modulate signaling by the Eph, DDR, and Tie receptors(Lemmon & 
Schlessinger, 2010; Mihai et al, 2009).  Understanding RTK signaling through non-autonomous 
pathways remains a highly active field of research, and these alternative signaling modes remain 
poorly understood. 
Roles in cancer and other diseases  
Given the widespread role of RTKs in driving proliferative processes in development, it is no 
surprise that anomalous regulation of RTKs underlies a wide variety of disease states.  Where 
loss-of-function mutations underlie diverse developmental and degenerative pathologies, gain-of-
function mutations are largely associated with cancer development and progression (owing to 
unchecked cell proliferation and survival).  Indeed, the ErbB and Met RTK sub-families (among 
others) were initially discovered as homologs of viral oncogenes(Dean et al, 1985; Sergeant et al, 
1982).  The important role of RTK signaling in cancer is reflected by the widespread development 
and clinical use of RTK inhibitors for cancer therapy.  To date, of the 20 RTK sub-families, only 5 
are not known targets of cancer therapy development: Ryk, MuSK, CCK4, LMR, and SuRTK106.  
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The majority of these ‘non-targets’ are kinase-compromised (Ror, Ryk, CCK4, and SuRTK106), 
and the remainder (MuSK and LMR) are not known to signal through autonomous ligand-receptor 
complexes(Mendrola et al, 2013).  Among the 14 RTK sub-families targeted in cancer therapy, 11 
are targeted by clinically-approved inhibitors, while the remaining three families (Trk, Axl, and 
Insulin receptor family) are targets of active clinical development(Alamgeer et al, 2013; 
D'Arcangelo et al, 2013; Festino et al, 2013; Haisa, 2013; Heldin, 2013; Hynes, 2009; Montero et 
al, 2011; Norris et al, 2011; Paccez et al, 2014; Scagliotti et al, 2013). 
Two major challenges for therapeutic RTK inhibition are well-known: specific targeting of RTK 
kinase activity is difficult to achieve due to the relative conservation across the human 
kinome(Festino et al, 2013; Gao et al, 2013), and resistance to RTK-directed therapies typically 
develops on a timescale of weeks or months(Hynes, 2009; Rosenzweig, 2012).  Most RTK-
directed small molecule therapeutics inhibit multiple kinases.  A broad range of kinase inhibition 
may actually be useful in many disease contexts, but it severely complicates the drug 
development process.  For example, off-target kinase inhibition may underlie undesirable side 
effects that limit dosing below a crucial therapeutic threshold.  RTK-directed therapeutic 
antibodies sidestep the kinase specificity problem by targeting the diverse extracellular regions of 
receptors with exquisite specificity.  Unfortunately, however, both therapeutic antibodies and 
small molecules directed at RTKs rapidly lose efficacy in treated patients.  The acquisition of 
specific, recurrent resistance mutations is a rapidly developing paradigm in cancer 
therapy(Rosenzweig, 2012).  One promising approach to combat resistance is rational 
combination therapy, in which drugs targeting a likely resistance pathway are co-administered 
with a drug targeting the primary oncogenic driver(Kwong & Davies, 2014).  Additionally, 
expanding our mechanistic understanding of RTK signaling should allow us to more potently and 
specifically target aberrant RTK signaling in cancer and other diseases. 
Whereas cancer therapeutics are designed to inhibit diverse RTK signaling pathways, there is a 
good biological rationale to develop therapeutic agonists of RTK signaling in other disease 
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contexts.  The classic example, of course, is insulin therapy for diabetes.  Beyond insulin, Tie1 
receptor stimulation has been investigated as a mechanism of supporting vascular integrity in 
sepsis(David et al, 2013).  Therapeutic potential for HGF, the ligand for Met, has been revealed in 
both a topical form for recurrent leg ulcers(Nayeri et al, 2002), as well as in gene therapy for 
treatment of chronic limb ischemia(Shigematsu et al, 2010).  Indeed, considering the widespread 
role of RTKs in vascular development, several RTK ligands have been investigated as therapies 
for ischemia(Hammer & Steiner, 2013).  In addition, great excitement has surrounded the recent 
discovery that Nrg1, an ErbB ligand, stimulates cardiomyocyte generation in the adult heart and 
aids recovery from heart failure(Bersell, 2009; Galindo et al, 2013; Hao et al, 2014).  The clear 
therapeutic promise of receptor tyrosine kinase drugs – whether inhibitors or agonists, specific or 
broad, small molecule or antibody – has prompted detailed mechanistic studies of RTK signaling. 
General mechanisms of signaling by receptor tyrosine kinases 
At the most general level, RTKs act as transmembrane receptors that convey an extracellular 
signal into the interior of the cell.  RTK extracellular regions (herein referred to as ECRs) directly 
bind to a ligand, resulting in increased effective kinase activity within the intracellular tyrosine 
kinase domain of the receptor (Fig. 2).  This is the core process of RTK signaling.  The increased 
effective kinase activity of RTKs contributes to intermolecular receptor trans-autophosphorylation, 
in which one receptor molecule phosphorylates another at defined tyrosine residues.  
Phosphotyrosines on the receptor are then specifically recognized by interaction modules in other 
signaling molecules that assemble active signaling complexes upon binding to activated receptor.  
These modules include Src homology 2 (or SH2) domains and phosphotyrosine binding (or PTB) 
domains.  Activated RTK signaling complexes exploit a handful of well-characterized pathways to 
broadly modulate gene expression, directly giving rise to the multitude of proliferative or 
differentiation events triggered by RTKs.  All the while, physiological RTK signaling is regulated at 
many levels.  Expression of both receptor and ligand is tightly controlled.  Constitutively active 
protein phosphatases at the cell membrane counteract the basal kinase activity of inactive 
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receptors (Sastry & Elferink, 2011).  Upon activation of receptor, down-regulation occurs through 
of variety of mechanisms. 
 
Figure 2: RTK ligands induce dimerization by diverse structural mechanisms.  Upon dimerization, 
the kinase domains within a dimer become activated.  An activated receptor kinase within one 
protomer proceeds to phosphorylate substrate tyrosines on its dimeric partner.  Receptor 
phosphorylation generally increases the inherent kinase activity (although ErbBs are an exception 
to this rule).  Receptor phosphotyrosines serve as docking sites for PTB- and SH2-domain 
containing proteins, which seed active signaling complexes.  
 
Ligand-binding and dimerization 
For the vast majority of autonomous RTKs, ligand-binding and receptor dimerization are 
intimately-linked processes that are thought to be tightly coupled energetically.  The single well-
established exception to this rule is the insulin receptor family, in which receptors are 
constitutively dimerized via an intermolecular disulfide bond(McKern et al, 2006).  In some 
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contexts, the ErbB family is prone to form ligand-independent dimers as well; this idea will be 
further examined later, and indeed is a primary focus of this thesis and the active work of others 
in the field (Chung, 2010; Gadella & Jovin, 1995; Saffarian, 2007; Tao & Maruyama, 2008; Webb, 
2008; Yu, 2002).  Incidentally, both of these receptor families are now known to utilize a unique 
structural mode of dimerization, in which the receptor dimer interface is formed exclusively by 
receptor protein surfaces; the contribution of ligand to dimerization is indirect(Garrett, 2002; Liu et 
al, 2012a; Ogiso, 2002).  At the opposite end of the spectrum, the ligand-dependent, extracellular 
dimerization interface that activates Trk receptors is exclusively ligand-mediated, with ligand 
acting as a bivalent, non-covalent cross-linker for two receptor molecules (Banfield et al, 2001; 
Wiesmann et al, 1999).   
Between these two extremes lie all the other structurally-characterized RTKs.  For these 
receptors, the homo-dimeric contacts that stabilize formation of an active dimer are distributed 
between both receptor-receptor contacts and ligand-ligand contacts, and even ligand-accessory 
molecule contacts in the case of FGFR, where the FGF ligands bind receptor and heparin 
concurrently(Ibrahimi et al, 2005).  The receptors Kit and VEGFR are two prototypical examples 
in which ligand-ligand contacts (within a bivalent ligand dimer) as well as receptor-receptor 
contacts contribute to the stability of active receptor dimers(Brozzo et al, 2012; Leppanen et al, 
2013; Yuzawa et al, 2007).  The relative topology of ligand-ligand and receptor-receptor contacts 
in these receptors (as well as PDGFR) is remarkably well-conserved(Yang et al, 2008).  The 
receptor-receptor contacts typically involve membrane-proximal regions of the receptor, whereas 
the ligand-ligand contacts involve more distal domains of the receptor, away from the membrane.  
There is some evidence that this sort of dual dimer-interface topology is important in ErbB 
receptors as well, even though both of the interfaces in this case are completely receptor-
mediated(Liu et al, 2012a; Lu et al, 2010; Moriki et al, 2001).  Although the relevance of this 
topology is not completely understood, there is some evidence that the membrane-proximal 
dimerization interface may play a role in specifying or constraining an activating dimer 
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relationship, rather than simply increasing dimerization affinity(Brozzo et al, 2012; Yang et al, 
2008). 
Kinase domain activation and trans-autophosphorylation 
Just as the ECRs of RTKs are activated through dimerization, so too are the intracellular kinase 
domains (Fig. 2).  Diverse mechanisms underlie the dimerization-dependent kinase activity of 
RTKs, and there is no general correlation between the respective modes of ECR dimerization and 
kinase activation within the RTK family.  Broadly speaking, kinase domains adopt an array of 
differently autoinhibited inactive conformations.  Receptor dimerization converts these inactive 
states, by a variety of different mechanisms, into an active kinase conformation that is largely 
conserved throughout the RTKs(Huse & Kuriyan, 2002).  For the ErbB receptor EGFR, 
dimerization of the kinase domain occurs in an asymmetric ‘head-to-tail’ arrangement that 
allosterically activates the kinase domain of one protomer(Zhang, 2006).   
For all the other well-characterized RTKs, auto-inhibitory intramolecular interactions suppress 
kinase activity by sterically blocking the active site; for these kinases, activation requires 
phosphorylation of key residues to interrupt the auto-inhibitory interaction(Lemmon & 
Schlessinger, 2010).  The residues involved in auto-inhibition may lie in the ‘activation-loop’ 
sequence within the kinase domain, the membrane-proximal juxtamembrane region (N-terminal 
to the kinase domain), or within the disordered tail of the protein, C-terminal to the kinase domain.  
For these kinases, it’s thought that a basal level of kinase activity (even when auto-inhibited) is 
sufficient to explain the phosphorylation events responsible for reversing auto-inhibition.  Within 
the high local concentration of receptor afforded by dimerization, this low level of activity is 
sufficient to trigger receptor activation through a first initial trans-autophosphorylation step.  
Following this first trans-autophosphorylation event within a dimer, an ordered and efficient 
sequence of further trans-autophosphorylation events ensues (Kim et al, 2012).   
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The number and location of trans-autophosphorylation sites varies by receptor.  Most are located 
in the C-terminal tail, the juxtramembrane region, or in the so-called kinase insert domain.  Some 
of these sites serve as direct docking sites for the SH2 and PTB domains of signaling molecules 
including PI(3)K, Shc, and Grb2(Schulze et al, 2005).  Other sites may serve as docking sites for 
receptor-specific ‘substrate’ proteins that function as scaffolding proteins; for these receptors, 
these substrate proteins are required for the full complement of signal transduction.  Such 
substrate proteins include the insulin receptor substrate (IRS) proteins, and the FGF receptor 
substrate (FRS) proteins.  There is emerging evidence that ligand identity and co-receptor 
engagement may modify the receptor phosphorylation pattern in a way that directs or modulates 
aspects of downstream signaling(Hartman et al, 2013; Wilson et al, 2012a).  Inevitably, RTKs 
directly stimulate signaling via the ERK and AKT pathways to regulate gene expression patterns.  
RTK modulation of STAT transcription factors has also been reported, but the mechanistic 
onnection is less clear and may be indirect(Gao et al, 2007). 
Exogenous regulation of RTK signaling activity 
A host of accessory factors in the cell serves both to suppress basal RTK signaling activity in the 
absence of ligand stimulation, and to down-regulate or terminate RTK signaling activity on a 
timescale of minutes.  Two well-known systems largely fulfill these roles.  One is the protein 
tyrosine phosphatase family (PTPs), which exhibit constitutive activity at the cell membrane to 
convert spurious phosphotyrosines back to benign tyrosine residues and to reverse the effects of 
ligand activation (Sastry & Elferink, 2011).  In addition, activated receptors are internalized by 
endocytic pathways, and are either degraded in the lysosome or de-activated by exposure to low 
pH in early endosomes before de-phosphorylation by PTPs and subsequent recycling to the 
plasma membrane. 
The PTP1B protein is a well-established suppressor of basal signaling for EGFR, Met, PDGFR, 
and IGF1R(Sastry & Elferink, 2011).  It has long been appreciated that general PTP inhibition (for 
example by orthovanadate or H2O2) leads to the rapid activation of RTKs, and more recent, 
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targeted studies suggest that PTP1B is primarily responsible for this effect (Elchebly et al, 1999; 
Tran et al, 2003).  PTPs in general, typified by PTP1B, seem to exhibit constitutive activity with 
very broad specificity(Stuible & Tremblay, 2010).  Given this apparent lack of PTP regulation, it 
should not be surprising that PTPs play a very complex and convoluted role in vivo.  In fact, it is 
clear that PTP1B is required for transforming activity in some contexts, so it is not simply a global 
inhibitor of signaling, but may have signal-promoting properties as well(Bentires-Alj & Neel, 
2007).  Another PTP, known as SHP2 or PTPN11, possesses two phosphotyrosine-binding SH2 
domains, which confer the ability to bind directly to RTK signaling complexes via direct interaction 
with the Gab adaptor proteins; however, SHP2 is not known to play any inhibitory role in RTK 
signaling, and instead seems to promote a variety of downstream signaling pathways(Sastry & 
Elferink, 2011).  Finally, the PTPN12 protein has also been shown to down-regulate RTK 
signaling pathways via its phosphatase activity, but it is not known whether it acts primarily on 
downstream signaling effectors or directly at the RTK(Charest et al, 1997). 
Once an RTK has been activated by ligand-induced trans-autophosphorylation, the receptor must 
be inactivated on an appropriate timescale to avoid perpetual signaling.  This inactivation is 
initiated primarily by the endocytosis.  Activated receptors are shuttled to early endosomes.  In 
some cases this results in ligand dissociation (due to low pH) and subsequent recycling of de-
activated receptor to the plasma membrane.  In other cases, low pH does not cause ligand 
dissocation, and the receptor is sorted to lysosomes where the receptor is proteolyzed and 
degraded.  Many different mechanisms have been implicated in activity-dependent RTK 
endocytosis, but the primary route under normal physiological conditions is though to depend 
largely on clathrin-mediated endocytosis (CME)(Goh & Sorkin, 2013).  Every major RTK family is 
known to become ubiquitinated, but the role of direct ubiquitination in CME is receptor-dependent.  
For example, whereas EGFR and FGFR-2 endocytosis do not depend on receptor ubiquitination, 
IGF1R endocytosis requires it(Mao et al, 2011).  When the concentration of activated receptor at 
the cell surface reaches extremely high levels (as in the case of cancer cells overexpressing 
receptor), the ubiquitin-dependent CME pathway becomes saturated, and other endocytic 
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pathways become relevant, although little is known about the relevance of these pathways in 
normal physiological conditions (Wiley, 1988). 
Biology of ErbB family RTKs 
 
Receptor knockout studies elucidate roles in cardiac and neural development 
Individual genetic deletion of the four mammalian ErbB receptors in mice demonstrates that all of 
these receptors play important roles in normal cardiac and neural development. Global knockout 
of ErbB2 or ErbB4 results in embryonic lethality at day E10.5 due to defective cardiac trabeculae 
formation, a process that depends on myocyte proliferation.  ErbB4 deletion also compromises 
development of hindbrain tissue, whereas ErbB2 deletion affects development of cranial neural 
crest-derived sensory ganglia(Gassmann, 1995; Lee, 1995).  Knockout of ErbB3 causes 
embryonic lethality at day E13.5, with pups exhibiting blood reflux through defective valves due to 
aberrant cardiac cushion formation. Trabeculae formation appeared normal for the ErbB3-null 
mice, but the hindbrain was once again severely compromised(Erickson, 1997).  Compared to the 
other ErbB receptors, ErbB1/EGFR seems to play a more global role in development.  EGFR 
deletion has strain- or background-dependent effects, resulting in either embryonic death due to 
placental abruption, or death three weeks after birth due to multiple organ failure, with defects in 
the skin, kidney, brain, liver, and the gastrointestinal tract(Threadgill et al, 1995).  Rescue of the 
strain-specific placental defect showed that a broad, strain-independent neurodegeneration 
program occurs soon after birth(Sibilia et al, 1998).  EGFR knockout mice also exhibit enlarged 
cardiac valves(Chen, 2000). 
Ligand knockout studies display complex phenotypes 
Not surprisingly, genetic deletion of ErbB ligands phenocopies ErbB receptor deletion in certain 
contexts; however, it is equally clear that some ligands are redundant in certain contexts.  There 
are nine discrete genes encoding a total of 11 distinct ErbB ligands (each Nrg gene has 2 splice 
isoforms), and each of these genes has been deleted in mice.  Among the ErbB ligand knockout 
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mice, the most striking phenotypes belong to HB-EGF- and Nrg1-null mice.  Global knockout of 
HB-EGF, a ligand for EGFR and ErbB4 that is expressed in cardiomyocytes, causes severe 
cardiac dysfunction typified by malformed heart valves (analogous to EGFR deletion) and 
considerable enlargement of the heart(Iwamoto, 2003; Jackson et al, 2003).  Although 
administration of HB-EGF to these mice caused increased phosphorylation of ErbB2 and ErbB4 
as well as EGFR, phenotypic comparisons indicated that Nrg1 is most likely to be the crucial 
ligand for ErbB2-heterodimer signaling in the heart. Genetic deletion of Nrg1 produces mice with 
defects in formation of trabeculae (as in ErbB2- or ErbB4-null mice) and the cardiac cushion (as 
in ErbB3-null mice)(Meyer, 1995).  Additionally, Nrg1-null mice exhibit defects in cranial ganglia 
and Schwann cell development, revealing an essential role for Nrg1 in ErbB2, ErbB3, and ErbB4 
signaling in the developing brain.  Although the low-affinity Nrg1α isoforms constitute the bulk of 
Nrg1 mRNAs in cardiac endothelial cells, specific knockout of these isoforms does not appear to 
impair heart development, suggesting that the high-affinity Nrg1β isoforms are primarily 
responsible for ErbB2-, ErbB3-, and ErbB4-mediated developmental cues in the heart(Cote, 
2005; Li, 2002). In addition to their role in cardiac development, ErbB2, ErbB4, and Nrg1 are 
crucial for adult cardiac function. Dilated cardiomyopathy occurs in mice with a cardiac-specific 
conditional knockout of ErbB2(Crone, 2002; Ozcelik, 2002) or ErbB4(Garcia-Rivello, 2005); both 
of these receptors are expressed in adult cardiomyocytes. Cell-based experiments lend further 
credence to the notion that Nrg1 signaling through ErbB2/ErbB4 complexes plays a unique role in 
cardiac physiology.  Moreover, cardiac toxicity has emerged as one of the most problematic side 
effects of ErbB2-targeted cancer therapy (Guglin et al, 2008). 
Phenotypes for other ErbB ligand-knockout mice are more convoluted.  In contrast to the 
dramatic cardiac effects of Nrg1 deletion, Nrg2 knockout mice are viable, and exhibit growth 
retardation and inefficient reproduction(Britto et al, 2004).  TGFα deletion yields a ‘wavy-hair’ 
phenotype, accompanied by abnormal follicle morphology(Luetteke et al, 1999).  Individual 
deletion of amphiregulin (Arg) results in defects in mammary gland development; deletion of EGF 
alone shows no overt phenotype, but combinatorial deletion of Arg and EGF shows a further 
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exacerbated mammary defect(Luetteke et al, 1999).  Even mice triple-null for EGF, Arg , and 
TGFα survive to maturity.  The final three ErbB ligands, Betacellulin (Btc), Epigen (Epg), and 
Epiregulin (Erg), have all been deleted in mice, and none of the resulting knockout mice display 
overt defects in development(Dahlhoff et al, 2013; Jackson et al, 2003; Lee et al, 2004).  The 
striking contrast in phenotypes for receptor deletion compared to ligand deletion (especially for 
EGFR, compared to its seven cognate ligands) has sparked the view that most of the ErbB ligand 
functions are covered by several-fold redundancies and constitute a robust developmental 
signaling sysem. 
Beyond development, recent studies have pushed forward our understanding of ErbB functions in 
mature animals.  These studies have primarily agreed with the view that most ligands are 
redundant.  For example, Epg, Erg, and Betacellulin have all been show to stimulate oocyte 
maturation in vivo(Park et al, 2004).  In response to corneal wounds, the ligands TGFα, Arg, and 
Betacellulin are all upregulated, and each can contribute individually to the wound healing 
response(Zieske et al, 2000).  Another striking hint at the combinatorial nature of ligand function 
comes from genomic conservation: the genes encoding Epg, Erg, Arg, and Betacellulin are all 
located adjacent to each other in mammal genomes(Lee et al, 2004).  This pattern in consistent 
both with a recent origin for these ligands via gene duplication, and with common regulation at the 
chromatin level. 
Mechanistic insight into ErbB signaling 
 
Signaling by the ErbB family underlies developmental processes in metazoans, from D. 
melanogaster and C. elegans to mammals(Freeman, 1997; Hill, 1992).  In adults, ErbB signaling 
plays a crucial role in homeostasis of the cardiac and reproductive systems as well as wound 
healing; aberrant ErbB signaling contributes to the development of cancer, heart disease, and 
neurological disorders.  Indeed, genes encoding EGFR and ErbB2 were first identified as 
oncogenes in the 1980s and have been viewed as important therapeutic targets in cancer ever 
since(Bublil, 2007).  The role of ErbB receptors in cancer, in combination with the discovery of 
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phosphotyrosine-based signal transduction in the 1980s, has motivated detailed mechanistic 
characterization of ErbB receptor-mediated signaling.   The ErbB/EGFR/HER family comprises 
four receptors and eleven bona fide ligands in humans.  ErbB receptors have a conserved 
domain architecture, with the extracellular, ligand-binding region encoding alternating -
helix/solenoid (domains I and III) and cysteine-rich domains (domains II and IV in humans).  The 
intracellular region consists of a short juxtamembrane region, a tyrosine kinase domain, and a 
regulatory but largely unstructured C-terminal tail.  A single transmembrane helix connects the 
extracellular region (or ECR) to the intracellular region (or ICR).   
Ligand stabilizes active receptor dimers and oligomers 
Groundbreaking studies employing cross-linking techniques with antibody-purified EGFR led to 
the proposal that EGFR (and, by extension, other ErbBs and RTKs in general) are activated by 
ligand-induced dimerization(Yarden & Schlessinger, 1987a; Yarden & Schlessinger, 1987b).  
Although a complete mechanistic understanding of ligand-mediated receptor activation is lacking, 
high-resolution crystallographic structural models of receptor fragments have greatly informed the 
current view (Fig. 3).  Crystal structures of all four of the ErbB receptor extracellular regions have 
been solved in the absence of ligand(Bouyain, 2005; Cho, 2002; Cho, 2003; Ferguson et al, 
2003; Garrett, 2003).  The EGFR ECR structure has also been determined in the fully ligand-
occupied state, with either EGF or TGFα as the activating ligand (Garrett, 2002; Lu et al, 2010; 
Ogiso, 2002), and a Nrg-activated ErbB4 ECR structure has recently been reported as well(Liu et 
al, 2012b).  All of the ligand-regulated receptors (EGFR, ErbB3, and ErbB4) exhibit a compact, 
‘tethered’ conformation in the absence of ligand.  The tethered conformation is stabilized by an 
intramolecular interaction involving a protruding -hairpin on domain II and a small surface on 
domain IV (adjacent to another, smaller, -hairpin).  The tethering interaction comprises 4-5 
hydrogen bonds involving conserved residues in domains II and IV.  In ErbB2, which exhibits an 
extended, untethered conformation in crystals and in solution(Dawson et al, 2007), these 
hydrogen-bonding residues are not conserved(Burgess, 2003; Cho, 2003).  ErbB2 cannot form 
17 
 
the autoinhibitory tether, and may therefore remain constantly poised to heterodimerize with other 
ligand-bound ErbB receptors. 
 
Figure 3: A model of ligand-induced dimerization and receptor activation based on crystal 
structures and solution scattering data.  A: tethered EGFR (adapted from crystal structure, PDB 
1NQL) B: ligated, extended, monomeric EGFR, inferred from low-resolution SAXS data (Dawson 
et al, 2007) C: ligated dimeric EGFR (adapted from crystal structure, PDB 3NJP). 
The independent structures of ligand-bound (presumably activated) EGFR  and ErbB4 ECRs 
show largely conserved ligand:receptor and receptor:receptor interactions(Garrett, 2002; Liu et al, 
2012b; Ogiso, 2002).  Ligand binds to surfaces from the -helix/solenoid domains I and III,  and 
stabilizes a rearrangement of the ECR from a tethered to an ‘extended’ conformation.  The ligand 
fold is stabilized by three characteristic intramolecular disulfide bonds, though much of its 
receptor-interaction surface is contributed by an otherwise unstructured C-terminal extension.  
The extended, ligand-bound receptor is competent for dimerization as illustrated in Fig. 3.  It is 
striking that the dimerization interface is dominated by the -hairpin ‘tether’ from domain II, which 
also stabilizes the inactive conformation.  Indeed, mutating the domain II -hairpin compromises 
the ligand-regulation of ErbB receptors in cells (Dawson, 2005).  An additional contribution to the 
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dimerization interface is made by residues near the N-terminal part of domain II.  Importantly, the 
EGF- and TGFα-bound EGFR structures differ significantly in this N-terminal part of the domain II 
dimer interface.  The origin and significance of this structural difference is currently unclear; it 
may arise simply from crystal packing differences, or as a consequence of the different receptor 
protein boundaries used in the two structures.  Alternatively, and as suggested by recent a recent 
study employing a conformation-specific imaging technique in cells (Scheck et al, 2012), the 
distinct ligands may inherently specify slightly different dimeric interfaces.  This could explain 
reported ligand-specfic signaling responses (Wilson et al, 2012a).  Biophysical studies argue that 
this portion of the dimer interface makes a small contribution to the overall dimerization 
energy(Dawson, 2005).  However, this does not mean that the structural difference is not 
biologically relevant.  Indeed, membrane-proximal contributions to dimerization of the Kit receptor 
have been shown to make little or no contribution to dimerization affinity per se (Lemmon et al, 
1997), but they do make crucial contributions to Kit activation – both by ligand and by oncogenic 
mutations (Yuzawa et al, 2007). 
ECR structures from the ErbB family argue that dimerization underlies ErbB signal transduction 
(Fig. 3).  Structures of intracellular regions argue that formation of an asymmetric dimer of the 
tyrosine kinase domains, in which one kinase domain allosterically activates the other, allows 
signal transduction to occur(Zhang, 2006).  The juxtamembrane region of the receptor also 
contributes to the stability of this asymmetric dimer(Red Brewer et al, 2009).  However, it is 
impossible at this time to fully reconcile our understanding of the ligand-mediated extracellular 
signaling events with the details and intricacies of intracellular kinase domain regulation (Lu et al, 
2012; Mi et al, 2011; Moriki et al, 2001; Roberts et al, 2012).  Domain IV of the ECR is highly 
flexible, especially in activated receptor dimers, so the orientation of receptors relative to the 
membrane remains an open question.  It has also been reported, using detergent-solubilized 
receptors, that the ligand-bound ECR can form an active dimer structure while the inhibitor-bound 
kinase domains remain monomeric (Lu et al, 2012). 
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While the structural models described above can inform and explain ligand-induced dimerization, 
kinase domain activation, and subsequent signal transduction, a wealth of observations 
suggesting that current structural models are far from sufficient.  First, numerous experimental 
methods have indicated the existence of pre-formed, inactive receptor dimers in the absence of 
ligand(Gadella & Jovin, 1995; Saffarian, 2007; Webb, 2008; Yu, 2002).  This observation 
undermines the simple model of receptor activation through ligand-induced dimerization.  The 
notion of physiologically-relevant, inactive, ligand-independent receptor dimers is bolstered by 
recent crystal structures and biochemical studies of the D. melanogaster EGF receptor(Alvarado 
et al, 2010; Alvarado, 2009).  Second, the complex binding characteristics of EGF and other ErbB 
ligands to cell-surface receptors, first noted 30 years ago, can not be explained based on the 
available structures(MacDonald, 2008; Ozcan, 2006; Shoyab, 1979).  It now appears that the 
complex ligand-binding characteristics reflect negative cooperativity, as seen in many receptor 
families (De Meyts, 2008).  The origin of this cooperativity – and its modulation by intracellular 
modifications (MacDonald-Obermann, 2009) – cannot be explained by simple dimerization 
models, because the crystal structures of human EGFR display symmetric ligand-binding sites.  
Third, there is evidence that distinct ErbB ligands induce distinct receptor responses at the level 
of phospho-tyrosine site usage and endocytosis kinetics(Hobbs, 2002; Roepstorff et al, 2009; 
Wilson et al, 2012a); these data suggest ErbB receptors can discriminate between ligands, which 
implies that multiple different activated receptor states may coexist. 
In combination, these three observations (ligand-independent dimers, negatively-cooperative 
ligand-binding, and ligand-specific receptor responses) strongly challenge the prevailing 
structure-based signaling model in which ligand-induced dimerization is the essence of ErbB 
receptor activation.  These challenges argue that subtle, unappreciated modes of allosteric must 
contribute importantly to the regulation of ErbB receptor activation.  The goal of my thesis was to 
further elucidate how ligand activates the EGF receptor through unappreciated allostery.  
Success in this regard would yield insight into the activation of ErbB receptors and other RTK 
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families, and it could also further inform the design of more effective ErbB-targeted therapeutics 
for cancer and heart disease. 
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CHAPTER 2: Probing the relationship between ligand-binding and EGF receptor 
dimerization and activation 
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Pre-dimerized EGFR requires ligand to form a domain II-mediated dimer 
 
 The structural model depicted in Figure 3 implies that EGFR activation is reducible to a 
ligand-induced dimerization event.  In contrast, recent findings from the D. melanogaster system 
imply that EGFR activation requires ligand-induced allosteric changes within a pre-formed, ligand-
independent dimer(Alvarado et al, 2010).  Extensive support for each of these models has been 
reported.  These two distinct models for understanding how ligand activates EGFR are not 
mutually exclusive, but they do have very important implications for therapeutic targeting of 
EGFR.  For example, development of therapeutic antibodies against EGFR has, to date, focused 
on selecting antibodies that prevent receptor dimerization.  If stable, inactive EGFR dimers form 
in tumors, then antibodies that stabilize such a complex might provide a unique therapeutic effect.  
While there is evidence that inactive, ligand-independent EGFR dimers are ubiquitous in a 
cellular context, the isolated human EGFR ECR (utilized for biochemical, biophysical and 
structural studies) does not form a ligand-independent dimer. To better understand how ligands 
can activate ligand-independent (‘pre-formed’ or ‘pre-dimerized’) EGFR dimers, we genetically 
fused a dimerizing Fc domain to the EGFR ECR for in vitro analyses.  This pre-dimerized EGFR, 
termed sEGFR-Fc, was amenable to thermodynamic, biophysical, and structural studies. 
 To determine the gross domain arrangement of pre-formed EGFR dimers, we collected 
and analyzed electron microscopy (EM) images utilizing uranyl formate negative-stain to generate 
contrast.  Class-averaging of single particles obtained from images of the sEGFR-Fc protein in 
complex with EGF yielded clear densities for all 4 receptor domains as well as the Fc domain and 
EGF (Fig. 4A).  The ligand-receptor complex itself bears a striking resemblance to previously 
published EM class-averaging results, for both isolated receptor ECRs and for near full-length 
receptors reconstituted in detergent micelles(Mi et al, 2011).  In a subset of classes, the Fc-
domain appears well-resolved with good signal, indicating that the particular arrangement of the 
Fc domain relative to the receptor domains represents a highly-populated state.  The relative 
position of the Fc domain in these classes is reminiscent of the relative position of the kinase 
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domains in near full-length receptors.  Thus, it is clear that pre-formed human EGFR dimers can 
form a domain II-mediated dimer in the presence of EGF. 
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Figure 4: A: Reference-free class averages generated in the Spider software suite, using single-
particle EM images of EGF:sEGFR-Fc complexes.  B: Rg values derived by Guinier analysis of 
SAXS data, or calculate from the structural models described in D-F using the HydroPro software.  
SAXS scattering was recorded for 10-20 µM sEGFR-Fc in the presence or absence of a 1.3-fold 
excess of EGF.  C: Dmax determinations, as previously described.  For B.) and C.), four 
independent experiments were performed, and the mean is plotted with error bars representing 
the standard error of the mean (SEM).  Paired t-tests were used to compare SAXS parameters in 
the presence or absence of EGF, and the p-values are indicated.  D-F:  Distinct structural models 
were constructed; Rg and Dmax values were back-calculated from these models using HydroPro, 
for comparison to experimentally-determined parameters for sEGFR-Fc. 
 
sEGFR-Fc without added ligand was also imaged by electron microscopy and particles were 
subjected to the same class-averaging algorithms as used for ligand-bound sEGFR-Fc (Fig. 5); in 
contrast to the results for the ligand-bound complex, sEGFR-Fc alone failed to generate signal-
enhanced class averages with well-defined and interpretable inter-domain relationships (even 
when using the exact same protein preparations).  This result reveals that a well-ordered, back-
to-back dimer, mediated by interactions involving domain II of each protomer, does not form in 
the absence of ligand.  It is not clear whether the individual receptor molecules with the Fc-
mediated dimer maintain a tethered or extended conformation, or represent an ensemble that 
samples multiple conformations.  These data do argue, however, that forcing dimerization of the 
EGFR extracellular region (by Fc fusion) does not simply drive it to form domain II-mediated 
dimers of the sort seen in our crystallographic studies of the D. melanogaster EGFR (Alvarado et 
al, 2010).  
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Figure 5: An example of a raw EM image file (in this case, sEGFR-Fc with no ligand) used for 
single-particle analysis.  For more details, see experimental methods. 
 
In an effort to better understand the allosteric effect of ligand-binding on pre-formed 
human sEGFR dimers, we also performed SAXS experiments on sEGFR-Fc in the presence and 
absence of EGF.  For sEGFR-Fc in complex with EGF, we determined the radius of gyration (Rg) 
by Guinier analysis and the maximal interatomic distance (Dmax) as described 
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previously(Dawson et al, 2007).  In the presence of EGF, the experimentally-determined 
scattering parameters are in good agreement with the parameters predicted from a structural 
model in which the previously observed back-to-back extended receptor dimer has an Fc domain 
dimer appended at the C-terminus of EGFR domain IV, with the Fc dimer extended away from 
the receptor (Fig. 4B-D).  In contrast, the sEGFR-Fc protein alone generates a scattering curve 
with a significantly larger Rg and Dmax.  These scattering parameters are most consistent with 
structural models in which the two receptor protomers in the unligated sEGFR-Fc dimer are not 
interacting in an ordered back-to-back dimer (Fig. 4E,F).  In agreement with EM data, these 
SAXS data suggests that sEGFR-Fc – and, by extension, physiological EGFR pre-formed dimers 
– requires ligand binding in order to form the domain II-mediated dimerization interface seen 
crystallographically for human and Drosophila EGFR.  This conclusion is further supported by 
recently published EM data on near full-length ligand-independent EGFR dimers – in which 
dimerization was driven by an EGFR kinase inhibitor rather than an Fc-fusion approach (Lu et al, 
2012).  In that case, antibody-labeling showed that the extracellular regions of the protein were 
conformationally heterogeneous.  The notion that ligand-independent EGFR dimers require ligand 
to form a stable, domain II-mediated dimer stands in surprising contrast to the allosteric activation 
mechanism describes for D. melanogaster EGF receptor (Alvarado et al, 2010).  Given our 
surprising findings, we sought to re-examine other key assumptions about dimerization-
dependent EGFR regulation, which were originally inferred from the structure-based model 
presented in Figure 3. 
EGFR dimerization does not stabilize ligand-binding 
 
As outlined in Fig. 3, the EGFR ECR monomer adopts a compact, tethered structure in the 
absence of ligand.  The intramolecular tethering interaction sterically blocks receptor dimerization 
by occluding the domain II dimerization interface.  Upon ligand-binding, receptor domains I and II 
move with respect to domains III and IV such that ligand can bind to surfaces on domains I and III 
simultaneously(Dawson et al, 2007).  This movement (a rigid body rotation about an axis close to 
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the domain II/III connection) exposes the domain II dimerization arm as shown in the middle 
panel of Fig. 3, and two 1:1 receptor:ligand complexes then form a symmetric homodimer (Fig. 
3C) with a dissociation constant of ~1 µM(Dawson, 2005).  This corresponds to a Gibbs free 
energy (∆G) of -7.5 kcal/mol for dimerization.  Several crystal structures support the views 
depicted in Figure 3 A and C for both EGFR and ErbB4(Bouyain, 2005; Burgess, 2003; Liu et al, 
2012a).  The structure of a ligand-bound, monomeric receptor has not been determined at atomic 
resolution and physiologic pH, but small-angle x-ray scattering (SAXS) data argue strongly that 
such a complex can adopt an extended, non-tethered conformation (as depicted in Fig. 3B), 
grossly reminiscent of one half of a 2:2 ligand:EGFR dimer(Dawson et al, 2007). 
To examine the energetic linkage of ligand-binding and dimerization for EGFR, we exploited 
isothermal titration calorimetry (ITC) to compare the thermodynamics of ligand-binding to either 
wild-type EGFR ECR (sEGFRWT, residues 1-618 of mature human EGFR) or the Y251A/R285S 
variant (sEGFRY251A/R285S).  sEGFRY251A/R285S does not dimerize upon ligand-binding, and this 
combination of mutations also abolishes signaling by the full-length receptor (Dawson, 2005; 
Ogiso, 2002).  Titration of the ligand EGF into sEGFRWT (Fig. 6A) and into sEGFRDomainIII (Fig. 7A) 
is consistent with previously published data.  Without the benefit of dimerization-deficient variants, 
these earlier studies interpreted wild-type titrations to represent enthalpically-driven ligand-
binding and strongly entropically-driven receptor dimerization(Alvarenga et al, 2012; Lemmon, 
1997).  It is clear, however, from the titration of EGF into the non-dimerizing sEGFRY251A/R285S 
variant that ligand-binding itself is driven by strongly favorable entropic terms (Fig. 6C).  This 
finding calls for a reinterpretation of previous thermodynamic studies of EGF/EGFR interactions.  
Based on a calorimetric dissociation experiment (Fig. 7B) the enthalpy of dimerization of ligand-
bound EGFR is <<|2| kcal/mol.  Because the dimerization enthalpy is insignificant in this context, 
sEGFRWT as well as sEGFRY251A/R285S titrations can be accurately fit with a single-site binding 
model, where the binding event represents ligand binding to receptor.  This thermodynamic 
pattern – namely, strongly entropically-driven ligand-binding, exaggerated by ~2 kcal/mol for 
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dimerization-deficient receptor – is maintained for the EGFR ligand TGFα, as well as EGF (Fig. 6, 
Table 1). 
Table 1 
EGFR variant Ligand  KDLigand-induced 
dimerization, µM 
KDLigand-binding, nM ∆HLigand-binding, 
kcal/mol 
Wild-type EGF ~1 41 ±12 +6.1 ±0.1  
 TGFα ~1 54 ±13  +6.1 ±0.1  
Y251A/R285S EGF >200 64 ±20  +7.9 ±0.2  
 TGFα >200 65 ±16  +7.6 ±0.3  
 
 
 
Figure 6: ITC titrations A: EGF titrated into sEGFRWT(5 independent experiments performed; 1 
representative titration is shown) B: TGFα titrated into sEGFRWT (2 independent experiments 
performed; 1 representative titration is shown) C: A structural illustration of the process occurring 
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during titration of ligand into sEGFRWT D: EGF titrated into sEGFRY251A/R285S (3 independent 
experiments performed; 1 representative titration is shown) E: TGFα titrated into sEGFRY251A/R285S 
(2 independent experiments performed; 1 representative titration is shown) F.  During ligand 
titration into sEGFRY251A/R285S, ligand binds to the receptor and the tether interaction is released, 
resulting in a relatively extended receptor conformation, but the receptor does not dimerize.  
Positions Y251 and R285 are highlighted in red.  An unpaired student’s T-test comparing the ΔH 
value for EGF binding to sEGFRWT and sEGFRY251A/R285S determined a p-value of 0.02, indicating 
high confidence that ligand-binding to sEGFRWT and sEGFRY251A/R285S is qualitatively and 
significantly different. 
Further insight into the relationship between ligand-binding and receptor dimerization can be 
gained by comparing the overall affinity of EGF for sEGFRWT and sEGFRY251A/R285S.  If the model 
in Fig. 3 is accurate, and monomeric, ligated receptor mimics one half of a 2:2 receptor dimer, 
then the Gibbs free energies of ligand-binding (-9.7 kcal/mol, based on a KD for ligand-binding of 
41nM) and receptor dimerization (-7.5 kcal/mol, based on a KD for dimerization of ~1M) should 
be additive; in other words, receptor dimerization should strongly stabilize ligand-binding, just as 
ligand-binding stabilizes dimerization in this simple model.  In the most extreme case, the KD for 
ligand binding to dimerizing receptor should therefore be nearly 6 orders of magnitude lower than 
for non-dimerizing receptor, corresponding to 7.5 kcal/mol of free energy gained from 
dimerization.    Contrary to this expectation, we find that the ligand-binding affinities for sEGFRWT 
and sEGFRY251A/R285S are equivalent within the sensitivity of the ITC experiment (Table 1).  This 
finding agrees with recent studies of ligand-binding to full-length receptor in cells, in which model 
fitting of EGF-binding data collected for cells expressing a wide variety of different receptor levels 
indicated negative-cooperativity, but a similar ligand-binding affinity for monomeric and dimeric 
receptor (MacDonald, 2008).  The notion that monomeric and dimeric receptors bind EGF with 
equivalent affinities is further supported by comparing the EGF-binding affinity for sEGFRWT 
determined by ITC with that determined by a fluorescence anisotropy (FA) assay, as illustrated in 
Figure 8D. The FA assay employs much lower receptor concentrations, well below the KD for 
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dimerization of ligand-bound sEGFR, so this assay effectively reports on EGF binding to 
monomeric sEGFRWT.  Nonetheless, EGF binds sEGFRWT with an affinity of 78nM in FA assays, 
arguing that its affinity for sEGFR is not affected significantly by dimerization per se.  Affinities for 
EGF binding to wild-type receptor in ITC (where the receptor dimerizes) and in fluorescence 
anisotropy assays (where sEGFR does not dimerize) are essentially the same, and equivalent to 
that measured by ITC for  the sEGFRY251A/R285S variant, arguing that receptor dimerization does 
not stabilize ligand-binding. 
 
Figure 7: A: ITC titration of EGF into 10µM sEGFR domain III.  Fitting to a single binding-site 
model yielded a KD of 3.1 ±1.9 µM, and a ∆H of -3.5 ±1.1 kcal/mol.  B: To measure the heat of 
ligand-induced dimerization, 17.5 µM sEGFRWT in complex with a 1.3-fold excess of EGF was 
injected into an ITC cell containing only buffer.  13 injections of 3 µL were performed, allowing 
measurement of dissociation heats in the ITC cell over an equilibrium concentration range of ~0.2 
– 2.4 µM for the sEGFRWT:EGF complex.  Because the heat of injection does not change 
systematically from the first injection to the last, and because the integrated heat of each injection 
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is so low (and can not be distinguished from instrumental noise), we conclude that the ∆Hdimerization 
for the sEGFRWT:EGF complex is <<|2| kcal/mol. 
 
Two independent lines of evidence argue that ligated, monomeric receptor is qualitatively distinct 
from one half of a 2:2 EGF:EGFR dimer.  If these two species were the same, dimerization of the 
two identical halves of the 2:2 EGF:EGFR dimer would lead to their mutual stabilization.  In other 
words, dimerization would stabilize the ligand-bound conformation, which would in turn be 
manifest as an enhancement of ligand binding upon dimerization.  As shown above, however, this 
does not happen.  It seems reasonable to argue instead, from the data outlined above, that 
dimerization of a 1:1 EGF:sEGFR complex must compromise ligand binding to each protomer to 
some degree.  Whereas monomeric, ligated receptor presumably adopts a conformation that 
maximizes ligand-receptor interactions, dimerization presumably compromises some of these 
interactions, so that ligand-binding and dimerization energies are not additive.  In other words, in 
order for dimerization to occur, some ligand-receptor contacts must be compromised.  We would 
therefore expect that the domain II conformation would be different (possibly very subtly) in the 
context of a 1:1 EGF:EGFR complex and a 2:2 EGF:EGFR dimer.  Second, the enthalpic 
signatures for EGF and TGFα binding differ significantly for sEGFRWT and sEGFRY251A/R285S (Fig. 
6 and Table 1).  Because dimerization does not contribute significantly to the measured 
enthalpies (see Fig. 7B), the difference in ∆H of ~2kcal/mol between sEGFR and the 
Y251A/R285S variant can be directly attributed to differences in ligand-binding.  The best 
explanation for this difference in ∆Hligand-binding is that the ligand:receptor interaction is qualitatively 
(and thermodynamically) distinct for monomeric and dimeric receptor.   KD values are very similar 
(64nM and 41nM respectively), so G differs by less than 0.23 kcal/mol.  Yet, H for EGFR 
binding differs by ~2 kcal/mol, being enthalpically less unfavorable in the case where dimerization 
is possible.  These observations argue that G for EGF binding to sEGFR dimers remains 
essentially the same as that seen for monomers because of a compromise between 
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enhancements as a result of dimerization and detractions as a result of restraints imposed upon 
the dimerizing sEGFR molecules. 
Regardless of the precise energetic origin of this effect, the equivalence of EGF and TGFα affinity 
for monomeric and dimerizing EGFR argues that driving EGFR homodimerization is not the 
primary function of EGF and TGFα – which contradicts the paradigm that has guided mechanistic 
thinking about EGFR for some time (Lemmon, 1997).  This has particularly important implications 
for understanding ligand activation in cells expressing the modest levels of EGFR typical in 
physiological conditions.  For cells expressing higher levels of EGFR (as in many cancers), 
however, pre-formed EGFR dimers are an important site of signaling, particularly at low ligand 
concentrations(Chung, 2010).  In this context, the monomeric ligand-bound receptor is less likely 
to form – raising the question as to how signaling through a pre-formed dimer is achieved. 
Pre-dimerized EGFR binds ligand with a high affinity driven by entropy 
 
The data presented above show that the process of dimerization does not increase ligand-binding 
affinity – with dimerization-defective EGFR binding ligands just as tightly as dimerizing receptor.  
However, several previous studies have indicated that forcing EGFR into a dimer can elevate its 
affinity for EGF.  Forcing the EGFR ECR into a constitutive dimer by appending a disulfide-linked 
Fc domain from human IgG1 has been reported to increase ligand-binding affinity relative to wild-
type receptor(Adams et al, 2009; Jones, 1999).  The presence of ligand-independent receptor 
dimers in cells, and the intrinsic ability of isolated EGFR kinase and transmembrane (TM) 
domains to dimerize (Jura, 2009; Mendrola et al, 2002), both argue that pre-formed EGFR dimers 
are an important species physiologically.  To investigate ligand-binding to pre-formed EGFR 
dimers, we have studied two distinct types of EGFR pre-formed dimers. 
To rule out any artifacts attributable to interactions of the Fc domain with receptor or ligand in an 
Fc-fusion, we studied not only a C-terminally-fused EGFR-Fc pre-formed dimer (‘sEGFR-Fc’), but 
also a C-terminal fusion of the leucine zipper from the S. cerevisiae transcription factor GCN4 to 
the EGFR ECR (‘sEGFR-Zip’).  A fluorescence-anisotropy (FA)-based experiment shows that 
34 
 
both the Fc-fused sEGFR and the zipper-fused sEGFR bind EGF with an affinity ~10-fold higher 
than wild-type (Fig 8D; Table 2).  The fact that sEGFR-Zip and sEGFR-Fc both bind EGFR with 
very similar KD values argues that the increase in ligand-binding affinity is a direct consequence 
of enforcing dimerization at the ECR C-terminus (equivalent to the region normally connected to 
the N-terminus of the TM domain in full-length receptor) and is not an artifactual consequence of 
any specific structural mode of dimerization, or of interactions between the dimerizing domain and 
either EGF receptor or ligand. 
 
Figure 8: ITC Titrations: A: EGF titrated into sEGFR-Fc B: TGFα titrated into sEGFR-Fc C: EGF 
titrated into sEGFR-Zipper D: Fluorescence anisotropy experiments, in which receptor variants 
are effectively titrated into a solution of Alexa-488-labeled EGF 
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Table 2 
EGFR 
variant 
Ligand  KDLigand-induced dimerization, 
µM 
KDLigand-binding, nM ∆HLigand-binding, 
kcal/mol 
Fc fusion EGF Constitutive dimer 7.8 ±2.5 +10.1 ±0.1 
 TGFα Constitutive dimer not determined +10.3 ±0.2 
Zipper fusion EGF Constitutive dimer 8.9 ±0.8 +12.8 ±0.2 
 
To better understand the origin of increased ligand affinity for pre-dimerized receptor, we again 
exploited ITC, titrating EGF into sEGFR-Fc (Fig. 8A) and sEGFR-Zip (Fig. 8C), or TGFα into 
sEGFR-Fc (Fig. 8B).  All titrations into pre-dimerized receptor showed an increased positive 
(unfavorable) enthalpy of binding relative to wild-type EGFR (Table 2).  Given the increased 
affinity of ligand for pre-dimerized EGFR, the ∆Sligand-binding must be significantly increased (more 
favorable) for pre-dimerized receptor.  This sort of entropic effect is easy to imagine, given that 
the pre-formed dimer will likely be more highly-ordered, exhibiting fewer degrees compared to the 
wild-type, monomeric receptor.  Whereas locking the wild-type (unconstrained, monomeric) 
receptor into an ordered dimer upon ligand-binding is predicted to be strongly-disfavored 
entropically, the entropic consequences of doing this for pre-dimerized sEGFR should be far less 
severe, since much of the entropic penalty will have been paid in forcing the dimer.  Thus, we 
conclude that pre-dimerized EGFR binds ligand more tightly by minimizing the entropic penalty of 
receptor dimerization. 
 Pre-dimerized EGFR exhibits two distinct binding sites in a temperature-
dependent manner 
 
 Upon closer inspection of titrations of EGF into sEGFR-Fc performed at 25⁰C we realized 
that they were ambiguous in the number of distinct binding sites that they suggested were 
present on the dimer.  In order to resolve this issue, we performed a series of EGF titrations into 
sEGFR-Fc over a temperature range of 10⁰C  to 30⁰C (Fig. 9).  Although most titrations employed 
10 M protein in the ITC cell, we also performed a 25⁰C titration of sEGFR-Fc at 25 M in order 
to increase signal-to-noise and improve confidence in our fitting (the considerable amount of 
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protein required prohibited us from using this concentration at other temperatures).  As a control, 
we performed titrations of EGF into sEGFRWT from 10⁰C to 25⁰C. 
 
Figure 9: ITC titrations of EGF into sEGFR-Fc and sEGFRWT from 10-30⁰C.  EGF titration into 
sEGFRWT at 30⁰C was not performed.  Unless otherwise noted, [receptor] was at 10µM in the ITC 
cell to begin the experiment, and data were fit to a standard single-site binding model.  Note: for 
sEGFR-Fc at 25⁰C, a 25µM [receptor] was used to improve signal-to-noise for more confident 
fitting; additionally, sEGFR-Fc titrations at 25⁰C and 30⁰C demanded a two-site binding model to 
obtain good fits to the data.  In each case, fitting to a two-sites binding model suggested equal 
stoichiometry for both sites, but the Kd and ΔH for each site can not be fit with precision.  The 
equivalent stoichiometry for each site suggests that these sites represent two independent ligand-
binding sites on an sEGFR-Fc dimer, and not a receptor dimerization event. 
 
The 25 µM sEGFR-Fc titration at 25˚C (Fig. 9), with improved signal-to-noise, argues that two 
distinct events are represented in the curve – justifying fitting of the data to two distinct binding 
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sites.  This conclusion is further strongly supported by the sEGFR-Fc titration at 30⁰C.  The 
appearance of two distinct binding sites, with different ΔHligand-binding values but equivalent 
stoichiometries (that sum up to a 1:1 EGF:sEGFR-Fc ratio) argues that, at temperatures above 
20⁰C, the two binding sites in an sEGFR-Fc dimer become inequivalent, suggesting asymmetry.  
Unfortunately, it is not possible to fit the distinct ΔHligand-binding and KD values for the two with any 
precision, because there are too many variables for the number of possible observables.  In 
contrast to sEGFR-Fc, sEGFRWT can be fit confidently with a single-site binding model throughout 
the temperature range tested (10⁰C  to 25⁰C).  This argues that enforced dimerization at the C-
terminus of the EGFR ECR (as is likely to occur in the full-length receptor, due to the intrinsic 
dimerization affinities of the tyrosine kinase and transmembrane domains) can be sensed by the 
ligand-binding sites on the receptor dimer. 
To examine whether the complex ligand binding we observed for sEGFR-Fc depends on 
allosteric communication of the two binding sites through the receptor domain II dimerization 
interface, we performed SPR and ITC binding studies with sEGFR-Fc bearing the Y251A/R285S 
double mutation that abrogates dimerization via domain II (abbreviated ‘OgFc’ in Figure 10C).  As 
shown in Fig. 10A and B, this mutation did not significantly affect the thermodynamics of EGF 
binding in ITC.  However, SPR binding data clearly show that the affinity of TGFα for sEGFR-Fc 
is affected by alterations inn the domain II dimerization interface; sEGFR-FcY251A/R285S binds 
TGF with an affinity that is 6-fold lower compared to sEGFR-Fc (Fig. 10C).  This result argues 
that the ligand-binding sites within sEGFR-Fc are sensitive to domain II-mediated interactions 
between protomers.  It is interesting that this effect is ligand-dependent.  EGF binds sEGFR-Fc in 
SPR studies with equivalent affinity regardless of the dimerization interface (Fig. 10C).  We 
conclude from these studies that pre-dimerized sEGFR – but not sEGFRWT – exhibits complex 
ligand-binding (which is consistent with weak negative cooperativity) at temperatures approaching 
physiological body temperature.  This observation may underlie the difference in binding behavior 
seen for human EGFR when studies of isolated, monomeric extracellular regions are compared 
with those focused on cell-surface EGFR. 
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Figure 10: A-B: ITC titrations of EGF into 10µM sEGFR-Fc (A.) and 10µM sEGFR-FcY251A/R285S 
(B.), which bears a compromised domain II dimerization interface.  For simplicity, titrations were 
fit to a single-site binding model.  C: SPR binding curves for sEGFR-Fc (‘WTFc’) and sEGFR-
FcY251A/R285S (‘OgFc’), flowed over a surface bearing EGF and TGFα on two different flow cells.  
Curves were fit to a single-site specific binding model in the Prism software, and fitted KD’s are 
displayed. 
 
Domain II:Domain IV intramolecular interactions stabilize inactive EGFR 
enthalpically 
 
The minimal ligand-induced receptor dimerization model depicted in Figure 3 initially led to the 
hypothesis that the intramolecular tethering interactions between domains II and IV of the inactive 
monomeric EGF receptor serve a crucial auto-inhibitory function (Burgess, 2003; Ferguson et al, 
2003).  It was proposed that this auto-inhibition occurs through stabilization of the tethered form 
of the EGFR ECR, which is compatible with neither high-affinity ligand-binding, nor the domain II-
mediated dimerization required for receptor activation.  Previous studies showed that mutations 
compromising the tether do indeed increase the ligand-binding affinity of the receptor, yet these 
receptor mutants are not constitutively-active in cells(Walker et al, 2012), and SAXS studies have 
shown that isolated sEGFR bearing these mutations maintain a compact, monomeric 
conformation incompatible with domain II-mediated dimerization(Dawson et al, 2007).  Although 
this proposed model for EGFR autoinhibition anticipated that activating oncogenic mutations 
might be found that disrupt autoinhibitory domain II/IV tether interactions, none have ever been 
found. Instead, cancer-causing ECR mutations that activate EGFR in vivo tend to cluster in the 
domain I/domain II interface (Lee et al, 2006).  These findings prompted us to test the view that 
the tether interaction stabilizes the inactive, compact form of the receptor.  To do so, we 
examined the thermodynamics of ligand-binding for a series of receptor ECR variants in which 
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the tether is compromised to varying degrees and which have different receptor dimerization 
affinities.   
Based on known structures, we would predict that mutations which disrupt the tether 
interaction should make ∆Hligand-binding more favorable by removing electrostatic and van der Waals 
interactions that enthalpically stabilize the unbound (tethered) state of the receptor (without 
contributing significantly to the dimerization).  The EGFR truncation consisting of mature receptor 
residues 1-501 (sEGFR501) has long been known to bind EGF with high-affinity (Elleman et al, 
2001) – indeed, when crystal structures first became available, it was clear that the complete 
abrogation of the tether interaction in sEGFR501 is likely responsible for this effect.  Because 
domain II remains intact, sEGFR501 still dimerizes upon ligand-binding in the same manner as the 
wild-type receptor.  We find that sEGFR501 binds EGF with a ∆Hligand-binding that is nearly 4 kcal/mol 
lower (more favorable) than wild-type receptor (Fig. 11A; Table 3).  This indicates a more-
favorable interaction, and is in good agreement with qualitative predictions from the crystal 
structure.  We sought to further test the role of the tether with a more modest mutation, in which 
domain IV is still present, to rule out thermodynamic effects arising from domain IV, which is 
known to play a role in receptor homodimerization(Kumagai et al, 2001; Lu et al, 2010).  The loop 
encompassing EGFR residues 575-584 constitutes a majority of the tether interaction surface on 
domain IV.  Deletion of this loop is known to increase ligand-binding affinity without a dramatic 
effect on ligand-induced dimerization(Dawson, 2005).  As with sEGFR501, we find that EGFR∆575-
584 exhibits an enthalpy of ligand-binding that is reduced (more favorable) relative to wild-type, by 
3.4 kcal/mol (Fig. 11B). 
Table 3 
EGFR variant Ligand  KDLigand-induced 
dimerization, µM 
 ∆HLigand-binding, 
kcal/mol 
1-501 EGF ~3  +2.2 ±0.2 
∆575-584 EGF ~2  +2.7 ±0.1 
246-253* EGF >200  +3.3 ±0.1 
246-253*/∆575-
584/D563A/H566A/K585A 
EGF >200  +2.5 ±0.1 
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Figure 11: ITC titrations of EGF into receptor variants A: sEGFR501  B: sEGFR∆575-584  C: 
sEGFR246-253* D: sEGFR246-253*/D563A/H566A/∆575-584/K585A 
 
The domain II surface that contributes to the inhibitory tether also constitutes the primary site of 
homodimeric interaction in ligand-bound receptor dimers.  A set of six point mutations in this 
region (Y246D/N247A/T249D/Y251E/Q252A/M253D) has previously been described, which 
disrupts both the tether interaction and ligand-induced dimerization(Garrett, 2002).  Like the 
truncation (sEGFR501) and domain IV (sEGFR∆575-584) mutations just described, a receptor protein 
incorporating these six mutations (sEGFR246-253*) binds EGF with a ∆Hligand-binding much lower 
(more favorable) than that of wild-type sEGFR, although the magnitude of the effect is slightly 
less, at 2.8 kcal/mol (Fig. 11C).  Combining these six point mutations in domain II with the domain 
IV tether-loop deletion and three additional domain IV tether-disrupting point mutations 
(sEGFR246-253*/D563A/H566A/∆575-584/K585A) yields a receptor mutant that displays a similar decrease in 
∆Hligand-binding as other tether-disrupting mutants, at 3.6 kcal/mol (Fig. 11D).  The striking similarity 
in thermodynamic and affinity effects of all four mutants described here emphasizes that our 
structural view of tether auto-inhibition is accurate, that domain IV contributes <1 kcal/mol to 
ligand-binding and dimerization, and that ∆Hdimerization is insignificant compared to ∆Hligand-binding. 
Transforming mutations in the EGFR ECR do not drive receptor dimerization 
 
The tether mutants described above were originally predicted to activate EGFR when the 
structures depicted in Figure 3 were first determined.  They fail to do so.  In contrast, several 
unexpected transforming mutations in the EGFR ECR were more recently discovered in 
glioblastoma tissue samples(Brennan et al, 2013; Lee et al, 2006).  Although numerous 
transforming mutations have been reported in the intracellular region of EGFR, most notably in 
lung cancer, these glioblastoma mutations are the first oncogenic driver mutations reported in the 
extracellular region.  EGFR bearing these mutations has been shown to transform NIH-3T3 cells 
and to increase proliferation in Ba/F3 cells (Lee et al, 2006).  These glioblastoma-causing 
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mutations cluster strikingly in the regions of EGFR domain I and domain II that form an intra-
molecular interaction surface in the tethered, inactive receptor (Fig. 13B).  In the ligand-bound, 
active form of the receptor, this intra-molecular interaction is subtly interrupted (lower part of Fig. 
13B).  To investigate the consequences of these mutations and understand how they lead to 
EGFR activation, we have examined the linkage of ligand-binding and dimerization for the most 
frequently-detected extracellular EGFR driver mutations in glioblastoma: R84K, A265D, and 
A265V. 
Because EGFR activation requires dimerization of the intracellular kinase domains, we 
hypothesized that activating extracellular mutations act simply by causing receptor dimerization in 
the absence of ligand.  Surprisingly, however, equilibrium analytical ultracentrifugation analysis 
shows clearly that sEGFR variants harboring any of the three tested mutants remain monomeric 
in solution (Fig. 12A).  Addition of TGFα results in dimer formation, with dimerization affinities 
equivalent to that of WT EGFR ECR.  It is clear that these mutations do not drive dimerization of 
unligated sEGFR to an appreciable extent (Fig. 12A; Table 4). 
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Figure 12: A: Sedimentation equilibrium AUC data at 9000 RPM for glioblastoma mutants plus 
and minus TGFα B: SPR binding curves for glioblastoma mutants over an EGF surface; sEGFR-
Fc has been included as a control C-E: ITC titrations of EGF into: C: A265D D: R84K E: A265V 
Table 4 
EGFR 
variant 
Ligand  KDLigand-induced 
dimerization, µM 
KDLigand-binding, nM ∆HLigand-binding, 
kcal/mol 
R84K EGF Not determined 4.3 ±0.9 +3.7 ±0.1 
 
A265V 
TGFα 
EGF 
1.5 ±0.6 
Not determined 
8.6 ±0.8 
16 ±4.7 
Not determined 
+4.1 ±0.1 
 
A265D 
TGFα 
EGF 
TGFα 
1.0 ±0.2 
Not determined 
4.8 ±0.6 
89 ±6.0 
8.6 ±3.0 
55 ±4.0 
Not determined 
+8.2 ±0.1 
Not determined 
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Whether these mutations activate EGFR by enhancing constitutive dimerization or not, we expect 
– given their location in the domain I/II interface – that they might alter the thermodynamics of 
ligand binding.  Indeed, mutations in this region of the Drosophila EGFR enhance its affinity for its 
ligands (Alvarado, 2009).  A mutated EGFR that has elevated ligand-binding affinity could be 
more ‘ligand-sensitive’, becoming activated by low ‘background’ levels of ligand that do not 
significantly activate WT EGFR.  Indeed, given that residues R84 and A265 in EGFR contribute to 
an intra-molecular interaction that is specific to the tethered form of the receptor, one would 
predict that mutating these residues might increase ligand-binding affinity (Figure 13B).  To test 
this hypothesis, we measured binding of sEGFRR84K, sEGFRA265D, and sEGFRA265V to EGF and 
TGFα using SPR.  All of these mutant forms bind to ligand with an elevated affinity (Fig 12B and 
Table 4).  Based on analysis of ligand-binding and ligand-induced dimerization, sEGFRR84K, 
sEGFRA265D, and sEGFRA265V are strikingly similar to the tether-disrupting mutants described 
above; however, they transform cells and cause cancer, whereas the tether-disrupting mutations 
have not been observed to do so. 
To extend this comparison, we performed ITC titrations to determine the energetic basis of 
ligand-binding to sEGFRR84K, sEGFRA265D, and sEGFRA265V.  Based on the structural model 
presented in Figure 3 and in analogy to tether-disrupting mutations, we would predict that each of 
these glioblastoma-derived point mutations increases ligand-binding affinity by enthalpically 
destabilizing the tethered state, resulting in a decreased (more favorable) ∆Hligand-binding for ligand 
binding to these mutants.  While this prediction holds true for sEGFRR84K and sEGFRA265V, where 
∆Hligand-binding is decreased (more favorable) by 2.0-2.4 kcal/mol, sEGFRA265D actually has an 
increased (less favorable) ∆Hligand-binding compared to sEGFRWT, by 2.1 kcal/mol (Fig. 12C-E, Table 
1).  These results clearly point to the domain I/domain II interface as an important site of 
autoinhibitory interactions in human EGFR – and one that is thermodynamically just as significant 
as the much discussed domain II/domain IV tether.  However, the specific effects on ∆Hligand-binding 
argue that the effect of mutating the domain I-domain II interface is complex, and cannot readily 
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be explained by the simple model presented in Figure 3.  More exploration of this interface is 
required, in parallel with analysis of more patient-derived mutations. 
The complex functional consequences of these mutations is consistent with cellular data 
showing that these mutations do increase basal EGFR signaling, while still retaining some ligand-
dependence.  It is difficult to fully exclude effects on receptor dimerization, since we would not 
detect unligated ECR dimerization with a KD above ~10-20 M in these studies.  A small increase 
in self-association affinity of the mutated ECR might be sufficient, combined with TKD and TM 
domain dimerization, to shift the balance towards significant constitutive dimerization of the intact 
EGFR in cells.  Synthesis of these data suggests that these mutations may, for example, be 
capable of tipping the equilibrium within ligand-independent EGFR dimers toward a more active 
signaling state, without strongly shifting the overall monomer-dimer equilibrium of the receptor 
ECR.   
Conclusions 
 
A great deal of investigation to this point, spanning from in vitro biochemistry and structural 
biology to cellular studies, has bolstered the view that dimerization is a crucial determinant of 
signaling within the ErbB receptor family – and throughout the larger family of receptor tyrosine 
kinases (RTKs)(Lemmon & Schlessinger, 2010).  EGFR-activating ligands drive receptor 
dimerizatio, aberrant receptor dimerization drives activation in many contexts, and preventing 
receptor dimerization with mutations or therapeutic agents plainly prevents receptor signaling.  
Accordingly, early reports of ligand-independent, inactive EGFR dimers within cells were met with 
uncertainty(Gadella & Jovin, 1995; Sako et al, 2000; Yu, 2002).  Recent crystallographic data, 
however, have captured a distinct inactive EGFR dimer that gives credence to the notion of 
physiologically-relevant, ligand-independent EGFR dimers(Alvarado, 2009).  This notion has clear 
precedent in the RTK family; insulin receptor forms a constitutive covalent dimer that remains 
inactive until insulin is bound(McKern et al, 2006; Menting et al, 2013), with activation presumably 
ensuing through intra-dimer conformational changes that have yet to be fully understood. 
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The outdated view that ligand-induced dimerization is the sole determinant of receptor activity (as 
depicted in Figure 3) has been invoked to argue that the primary function of EGFR ligands must 
be to induce receptor dimerization.  An important corollary of this simple argument is that ligand 
must bind more tightly to dimerizing receptor than to monomeric receptor.  Our binding data 
clearly show that the EGFR ligands EGF and TGFα bind monomeric and dimerizing receptor with 
equivalent affinities, and this data is supported by recently published cellular data (MacDonald, 
2008).  The enthalpy of ligand-binding, however, is significantly different for monomeric sEGFR 
compared to the dimerization-capable sEGFR for both EGF and TGFα.  The enthalpy data argue 
that EGF and TGFα bind to sEGFR to form an initial complex that is qualitatively distinct from 
one-half of a ligand-induced receptor dimer.  The weak energetic coupling of ligand-binding and 
dimerization, conserved for EGF and TGFα, further argues that functional constraints other than 
driving EGFR homodimerization have driven ligand evolution.  These data show that the 
qualitatively distinct and poorly understood conformation of a 1:1 ligand:EGFR complex (see 
Figure 13) is relevant to receptor function. 
Figure 13A 
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Figure 13B
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Figure 13: A: An expanded schematic model for ligand activation of EGF receptor, based on data 
presented here.  When ligand binds to monomeric EGFR, it preferentially populates a receptor 
state (in purple) that is not configured for optimal receptor homodimerization.  The true 
conformation of this state is not known at atomic resolution.  This EGF:EGFR state favors binding 
to ErbB2 to yield an EGF:EGFR:ErbB2 heterodimeric signaling complex.  Alternatively, EGF can 
bind (with a lower affinity) to a receptor state (in pink) that is identical to the EGFR state within a 
homodimer.  Pre-formed, inactive EGFR dimers (at right) are activated by a related but unique 
pathway; in the absence of ligand, the extracellular regions of the receptor do not form an ordered 
dimer.  Ligand-binding induces formation of the receptor domain II-mediated extracellular dimer. 
B: Comparison of active (blue; PDB 1IVO) and inactive (pink; 1YY9) crystal structures points to 
an allosteric regulatory role for the domain I:domain II interface in ligand-binding and dimerization.  
A similar alignment with all three known structures of ligand-activated ErbB receptors and all four 
known structures of inactive EGFR and ErbB4 (not shown) illustrates that this pattern is strictly 
conserved.  These alignments show exquisite structural conservation of the A265 sidechain, 
which is buried in a hydrophobic interface between domain I and domain II.  Mutation of this 
sidechain to a bulky residue is predicted to structurally disrupt this interface; to accommodate 
extra methyl- or carboxyl- groups, the protein backbone in the A265 region must translate away 
from domain I, mimicking the structural effect of ligand-binding in this region.  Although the R84 
sidechain is less-conserved structurally, it can form hydrogen bonds with domain I and domain II, 
providing a structural bridge between these domains which may be disrupted upon mutation. 
 
What is the nature and the functional relevance of a 1:1 ligand:EGFR complex?  Shaw and 
colleagues have run microsecond molecular dynamics simulations that suggest such a complex 
forms a tethered-like structure in which a (previously unobserved) kink occurs near the N-
terminus of domain IV(Arkhipov et al, 2013).  Accordingly, they have proposed a model 
(consistent with binding data presented here) where the primary function of ligand is not to drive 
receptor dimerization through domain II, but rather to eliminate steric autoinhibition of a TM- and 
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kinase-domain-driven dimer.  Such a model, however, cannot account for the ability of a solitary 
extracellular point-mutation (Y246D) in the domain II dimerization interface to completely 
abrogate ligand-induced receptor signaling(Walker et al, 2012) – which argues that domain II-
mediated dimerization is crucial for receptor signaling activity.  Moreover, one complication in 
interpreting the Shaw laboratory simulations is that they predict the stability of complexes (such 
as unligated sEGFR dimers) that have never been observed experimentally – indicating that key 
elements have been misestimated. 
A more satisfactory explanation for the functional importance of a 1:1 ligand:EGFR complex 
recalls the primary importance of heterodimeric EGFR signaling complexes.  Indeed, it has long 
been thought that EGFR ligands will preferentially signal through EGFR:ErbB2 heterodimers 
when applied to cells expressing the full complement of ErbB receptors.  These observations 
sparked the notion that this preference may arise from a simple biophysical preference of ligand 
for the heterodimer; experiments utilizing isolated receptor ECRs, however, argued against this 
simple hypothesis (Ferguson, 2000).  Importantly, more recent measurements have been made 
in the context of full-length receptors expressed in cells.  Here, EGF binds more tightly to EGFR 
within an EGFR:ErbB2 heterodimer, relative to an EGFR homodimer(Li et al, 2012) – presumably 
reflecting contributions of the TM and intracellular domains (as well as possible membrane 
contributions) to receptor heterodimerization.  We propose that the 1:1 ligand:EGFR complex in 
solution adopts a conformation (Figure 13A, purple) mimicking that within a ligand:EGFR:ErbB2 
complex in cells.  This could explain the need for EGF and TGFα to maintain a high affinity for 
monomeric EGFR.  Binding data presented here, combined with exciting new data from cellular 
studies, thus calls for a more detailed investigation of ligand binding to monomeric and 
heterodimeric EGFR. 
We initially hypothesized that ligand-independent EGFR dimers mimic those observed 
crystallographically for the D. melanogaster EGF receptor (dEGFR).  By fusing dimerizing 
domains to the EGFR ECR, we created ligand-independent EGFR dimers in solution.  These 
dimers, surprisingly, still require bound ligand to form a well-ordered, domain II-mediated dimer 
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interface.  Preliminary ligand-binding data suggest that the EGFR ECR within sEGFR-Fc is 
significantly tethered (data not shown).  Thus, these forced human sEGFR dimers do not seem to 
mimic dEGFR. It is clear from the high affinity of these dimeric fusion proteins for ligand, and the 
EM images of the dimeric complexes that they form, that they are perfectly compatible with the 
crystallographically-observed active dimer structure depicted in Fig. 3C, and that our fusion 
approach has not compromised the receptor.   These observations, in combination with the high 
local concentration of EGFR ECR within sEGFR-Fc (at least ~1 mM, and potentially much higher 
depending on orientation effects) provide the strongest argument to date that ligand binding to the 
EGFR ECR actively remodels the domain II dimerization interface into one capable of dimerizing, 
rather than simply capturing a transient extended EGFR conformation.  The long-standing 
observation that sEGFR501 (in which domain II should be free to dimerize) fails to dimerize in the 
absence of ligand, further bolsters this view.  Active allosteric remodeling of receptor by ligand, 
specifically within the dimerization interface, is an important prerequisite for models of ligand-
specific signaling in which unique ligands induce subtly different receptor states or select for 
specific heterodimer signaling complexes(Wilson et al, 2009).  Accordingly, our data (contrary to 
the minimal model in Fig. 3) suggest that such models are indeed feasible – and that there is 
much more to ErbB activation that just ligand-induced dimerization.  Available crystal structures 
do show some differences in domain II conformation that depend upon ligand.  For example, 
ligand-binding induces or stabilizes a curvature along the long axis of domain II that facilitates 
symmetric homodimer contacts (Fig. 13B).  Unfortunately, the small magnitude of these 
differences, the relatively low resolution of the available structures, and the lack of multiple 
different ligand-complex structures for a given ErbB receptor protein has prevented more 
sophisticated structural analysis of ligand-induced allostery in domain II so far.  For example, a 
structure of a monomeric ligand-bound EGFR would provide insight into whether structural 
changes in domain II are primarily driven by ligand-binding or by homodimerization.  Intriguingly, 
it has been reported that an ErbB ligand bearing a specific point-mutation can function as a 
receptor antagonist(Wilson et al, 2012b).  Furthermore, recent data from conformation-specific 
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fluorescent reporters have suggested that different EGFR ligands (EGF vs TGF) induce unique 
structures in the intracellular regions of the receptor(Scheck et al, 2012).  Additionally, ligand-
specific phosphorylation-site usage and cellular output has been reported(Wilson et al, 2012a).  
Ligand-specific domain II-mediated receptor dimers would provide the most restrained 
explanation for these observations, and further suggest that an approach of modifying ErbB 
ligands – selecting for either inhibitory or (very specific) agonist activities (for example, stimulating 
EGFR:ErbB2 heterodimers but not EGFR homodimers, or vice versa) – may yield useful reagents 
for modulating ErbB signaling experimentally and therapeutically. 
Another prediction of the minimal structural model in Fig. 3 is that activating mutations in 
the EGFR extracellular region must act by simply inducing receptor dimerization.  We report here 
that the most common extracellular EGFR transforming mutations (R84K, A265V, and A265D) fail 
to drive sEGFR dimerization in the absence of ligand.  On the other hand, these mutations clearly 
enhance ligand-binding.  Given that these mutations increase proliferation in Ba/F3 cells, in which 
ErbB ligands are undetectable (and in which tether-disrupting EGFR mutations, which increase 
ligand-binding affinity to a similar extent, are not transforming), these mutants likely exhibit a 
mechanism of activation beyond simply increasing ligand-binding affinity.  Accordingly, it is 
important to note that the EGFR domain I/domain II interface, compromised by these activating 
glioblastoma mutations, is an obvious potential route for allosteric communication between the 
ligand-binding sites and the dimerization interface (Fig. 13B). 
In inactive crystal structures, R84 can form a highly geometrically-constrained hydrogen bonding 
network that bridges R84 and E60 on domain I to the backbone of residue C227 in domain II (Fig. 
13B).  Upon ligand-binding and dimerization, the hydrogen bond between R84 and C227 appears 
to be compromised, with the interatomic distance increasing by 1Å.  Perhaps more strikingly, the 
A265 sidechain is buried in a hydrophobic interface between domain I and domain II in the 
inactive tethered conformation; ligand-binding and dimerization wedges domain II outward, 
exposing the A265 side-chain to solvent.  Furthermore, in the alignment in Figure 13B, the 
inactive and active structures begin to diverge considerably around residue T239 and beyond; 
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though not studied here, a T239P mutation was also reported to cause EGFR activation and drive 
glioblastoma.  We propose that the domain I/domain II interface represents an auto-inhibitory, 
allosteric interaction that maintains the domain II dimerization interface in an inactive, 
dimerization-incompetent conformation (Figure 13B).  All of the oncogenic mutations described 
here could be rationalized by this model: the R84K mutation will eliminate a hydrogen-bond, 
weakening the linkage between domain I and domain II; mutating A265 to V or D will introduce a 
bulky side-chain that cannot be accommodated in the tightly-packed hydrophobic interface, 
effectively wedging the two domains apart much like the effect of ligand-binding; the T239P 
mutation will introduce atypical backbone geometric constraints in a hinge-like region that shifts 
upon activation.  Accordingly, perturbing this interface generally may increase the basal activity of 
otherwise inactive pre-formed EGFR dimers (Figure 13) without necessarily driving receptor 
dimerization. 
Taking a broad view of the data reported here, it becomes clear that EGFR ligands exhibit subtle 
and poorly understood allosteric regulation of EGFR function.  As the primitive model depicted in 
Figure 3 has been largely debunked, the development and testing of more powerful structural 
models of ErbB signaling that can account for ligand-specific signaling outputs (either by ligand 
discrimination within a given homo- or heterodimeric complex, or by ligand selection of a specific 
signaling complex), complicated ligand-binding patterns, and inactive ligand-independent dimers 
is necessary.  Our observations motivate further study (by showing that such allosteric regulation 
is not only feasible, but likely contributes to EGFR pathology) and offer a novel, refined model of 
ligand-dependent EGFR signaling. 
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CHAPTER 3: Characterizing signaling by diverse EGF receptor ligands 
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The data presented in Chapter 2 elucidate a complex mode of allosteric regulation well 
beyond the scope of the minimal structure-based model for ligand-induced dimerization.  Where 
the minimal model fails to explain why seven different EGFR ligands are present in mammals, the 
allosteric regulation uncovered in this thesis hints that receptor complexes could potentially 
discriminate between the individual unique ligands.  Unique ligands may induce unique receptor 
dimers upon binding – at the level of conformation or dynamics.  Many observations in the 
literature are consistent with just such a mechanism. 
Multiple studies have found ligand-dependent differences in receptor internalization 
rates(Roepstorff et al, 2009; Willmarth et al, 2009).  This difference is particularly stark for the 
ligands Erg and Arg, which stimulate lower levels of receptor internalization than EGF.  Since 
ligand-induced receptor internalization and degradation are largely mediated by receptor 
ubiquitination and c-Cbl binding at pY1045 on EGFR, these studies further examined these 
events.  While both studies found differences in c-Cbl binding and ubiquitination for Arg-receptor 
complexes compared to EGF-receptor complexes, the two studies are not self-consistent; one 
reports increased ubiquitination of, but decreased c-Cbl binding to, Arg complexes, while the 
other reports decreased ubiquitination of Arg complexes.  Both studies observe that the temporal 
stability of specific EGFR phosphotyrosines differs for Arg complexes compared to those induced 
by EGF.  Importantly, neither of these studies has definitively pinpointed the origin of ligand-
dependent ubiquitination and c-Cbl binding patterns.  The simplest possible explanation for this 
difference would be unique, ligand-dependent receptor phosphorylation-site usage. 
Further support for unique ligand-dependent receptor complexes comes from a structure-
dependent imaging technique described by the Schepartz laboratory (Scheck et al, 2012).  
Briefly, a unique fluorescent reporter was employed that emits a fluorescent signal only when 
coordinated by four cysteine residues.  Scheck et al. measured reporter fluorescence for a series 
of ligand-bound EGFR variants in cells, with cysteines inserted at various positions within the 
intracellular JM region.  They report that EGF and HB-EGF receptor complexes showed high 
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fluorescence for one discrete set of EGFR cysteine variants, whereas TGFα complexes showed 
high fluorescence for a distinct set of EGFR cysteine variants.  This observation argues that 
TGFα induces a unique intracellular receptor dimer structure compared to EGF and HB-EGF.  
Further work in cells has suggested that different ErbB ligands are differentially coupled to DNA 
synthesis, proliferation, and survival in cell culture (Hobbs, 2002; Wilson et al, 2012a). 
While the studies summarized above are all consistent with ligand-dependent receptor 
complexes that possess unique signaling qualities encoded exclusively by the ligand-receptor 
complex, other possibilities must be considered.  For example, the pH-dependence of ligand 
binding is known to affect receptor down-regulation, which may modulate steady-state receptor 
signaling at qualitative and quantitative levels (French et al, 1995).  Accordingly, unique ligands 
may exert unique signaling effects by possessing unique pH-dependence profiles without 
inducing any unique receptor signaling state.  Additionally, many of the studies cited above have 
employed cell lines expressing multiple ErbB receptors; ligand-dependent signals may be a result 
of unique receptor-binding specificities for the different ligands. 
A primary challenge in understanding the capacity for EGFR to functionally discriminate 
between ligands has been the difficulty in obtaining reagents.  EGF and TGFα are both readily 
expressed in E. coli and have been available from commercial suppliers for some time.  Other 
ErbB ligands, however, do not express at high levels, and many years of work in the Lemmon 
laboratory and elsewhere has failed to produce large quantities of high-quality protein for 
biophysical studies.  Remarkably, for biophysical studies of ErbB receptor signaling, generating 
the 50-100 amino acid ligand proteins has consistently been much more of a challenge than 
producing the 600-800 amino acid receptor extracellular regions.  Although some of the ErbB 
ligands are nonetheless commercially available, cost is prohibitive for the sort of structural and 
biophysical experiments required to shed light on ligand-dependent allosteric effects.  Moreover, 
the quality of expensive material that has been purchased by the Lemmon laboratory in the past 
has been found to be wanting – making this not a feasible route in any case. 
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To overcome these challenges, I have successfully employed a unique fusion protein 
approach (inspired by our experience with invertebrate ligands) to successfully express the ErbB 
ligands amphiregulin (Arg), epiregulin (Erg), and Epigen (Epg).  The yields I have achieved are 
suitable for structural and biophysical analyses.  I have observed that my recombinant Arg, Erg, 
and Epg are all capable of inducing EGFR phosphorylation in cell culture.  Additionally, I have 
performed a series of ligand-binding studies with EGFR variants in analogy to studies described 
in Chapter 2.  In results reminiscent of recent findings concerning ligand-binding to VEGF 
receptors (Brozzo et al, 2012; Leppanen et al, 2011; Leppanen et al, 2010), I find that the 
thermodynamics of ligand-receptor binding are highly ligand-dependent.  This result stands in 
stark contrast to the results reported in Chapter 2, where the thermodynamics of receptor binding 
are strikingly similar for EGF and TGFα (with the exception of binding to the ‘OgFc’ variant, in 
Chapter 2, Fig. 10C).  Finally, my results illustrate that Epg and Erg exhibit coupling to EGFR 
variants in a way that differs significantly from EGF and TGFα.  My results thus suggest 
mechanisms by which unique ErbB ligands may elicit qualitatively unique receptor responses. 
Recombinant production of bio-active EGFR ligands Epigen, Epiregulin, and 
Amphiregulin 
 
Much effort in the Lemmon laboratory has been directed at the recombinant production of 
EGFR ligands in insect cell expression systems.  Previous work indicated that the presence of the 
low-complexity leader sequence of Spitz (a ligand for D. melanogaster EGF receptor) was 
essential for high levels of recombinant protein production in Sf-9 cells.  We reasoned that this 
leader sequence was required for the proper folding and secretion of EGF-like domains in insect 
cells.  Accordingly, I made a series of plasmids encoding the EGF-like domains of human EGFR 
ligands following the Spitz leader sequence, with a protease-site for subsequent purification of the 
isolated EGF-like domains (Fig. 14A).  This expression cassette was inserted into the pFastbac 
plasmid for generation of baculovirus for expression in Sf-9 cells, as well as the pMT vector for 
expression in S2 cells. 
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Figure 14: Generation and validation of recombinant Arg, Erg, and Epg produced in insect cells. 
A: Architecture of the protein-coding constructs used for recombinant ligand production. B-C: 
Coomassie-stained gels showing representative samples of purified Arg (B.) produced in Sf-9 
cells, and Epg (C., left) and Erg (C., right) produced in Drosophila S2 cells.  These gels show the 
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protein after Ni-NTA agarose, cation-exchange, and gel filtration purification steps.  Erg and Epg 
were further purified by sequential filtration through 50 kDa- and 30 kDa-molecular weight cutoff 
protein concentrators (Amicon), which removed the majority of high molecular weight 
contaminants (see Epg gel, +/- filtration step).  Lanes D-F: Stimulation of EGFR-overexpressing 
cell lines by recombinant ligands.  ‘Null’ lanes were mock-stimulated with serum-free DMEM 
media.  D: A431 cells (which overexpress EGFR) were stimulated on ice for 10 minutes with 
either 100nM EGF, 5µM Spitz-Arg, or 5µM Arg EGF-like domain alone (‘Arg-EGF’), to ensure 
saturation of receptor.  Arg-EGF was created by FxA-mediated cleavage and subsequent NiNTA-
mediated removal of the Spitz leader sequence.  Clarified lysates (right) and Concanavalin-A-
agarose pull-down samples (enriched for glycosylated proteins) were probed on a western blot 
using the pY20 antibody, which broadly detects phosphotyrosine residues.  E-F: MDA-MB-468 
cells (which overexpress EGFR) were stimulated on ice for 10 minutes with increasing 
concentrations of EGF, Epg (E.), and Erg (F.).  Clarified lysates were probed on western blots 
using the pY20 antibody. 
 
I found that this Spitz-fusion approach allowed high-level expression of Arg in Sf-9 cells 
(Fig 14B), and Erg and Epg in S2 cells (Fig 14C).  For initial tests of signaling activity, I purified 
the ligands by Ni-NTA agarose affinity, cation-exchange chromatography, and size-exclusion 
chromatography.  After these purification steps, the final yield for all three ligands is on the order 
of 0.1-0.5 mg per liter of culture media – better than has been achieved in the laboratory in over 
15 years of trying, and with much more homogeneous material.  In order to test the activity of 
these ligands, I incubated cell lines expressing high levels of EGFR on ice for 10 minutes with no 
ligand (‘Null’ samples), or with purified Arg, Erg, or Epg, or with EGF as a positive control.  
Ligands were tested at concentrations up to 5µM to ensure receptor saturation.  Arg was tested 
side-by-side with EGF on A431 cells, and both cell lysates and concanavalin-A pulldowns 
(enriched for glycosylated proteins, including EGFR) showed a similar extent of EGFR activation 
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for Arg- and EGF-stimulated samples (Fig. 14D).  Since Arg stimulated EGFR regardless of the 
presence of the Spitz leader sequence, subsequent studies with Arg, Erg, and Epg all left the 
Spitz leader sequence intact.  Similarly, Erg and Epg were tested on MDA-MB-468 cells, and 
showed a similar extent of EGFR activation compared to EGF (Fig. 14E-F).  These results 
illustrate that the ligands Arg, Erg, and Epg may be produced in high quantity and quality (as 
judged by signaling activity) in insect cell lines using the Spitz fusion approach. 
Epigen, Epiregulin, and Amphiregulin bind to EGF receptor with unique 
thermodynamic profiles 
 
EGF and TGFα exhibit exquisitely well-conserved thermodynamics in binding to 
constitutively-monomeric, constitutively-dimeric, and wild-type sEGFR.  This level of conservation 
– in which the enthalpies, entropies, and free energies of ligand-binding are all conserved within 
0.5 kcal/mol for all three receptor variants – seems to suggest that EGF and TGFα impart a well-
conserved and functionally important allosteric regulation on EGFR.  In contrast, the dependence 
of TGFα affinity upon the domain II dimerization interface of sEGFR-Fc hints that ligand-specific 
effects may be relevant for EGFR, since EGF affinity is independent of domain II in this context 
(Chapter 2, Fig. 10C).  Recent reports of a TGFα-specific receptor conformation in cells would 
suggest that EGF- and TGFα-binding should be quite different, although there may be cellular-
kinase-, and transmembrane-determinants that are missing in our in vitro binding studies (Scheck 
et al, 2012).  Interestingly,  it was recently observed that ligand-binding enthalpies for VEGFR-2 
binding to VEGF-A, VEGF-C, and VEGF-E vary by up to 7kcal/mol, reflecting differences 
observed in ligand-VEGFR-2 crystal structures(Brozzo et al, 2012; Leppanen et al, 2011; 
Leppanen et al, 2010). 
Given our interest in understanding whether different EGFR ligands engender distinct 
responses by forming unique receptor complexes via allosteric regulation, we sought to measure 
the thermodynamics of sEGFR-Fc-binding for Arg, Erg, and Epg.  We reasoned that functionally 
unique receptor-ligand complexes might be manifested as unique patterns of ligand-binding 
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energies.  For example, hydrogen bonds and salt bridges contribute to the enthalpy of ligand-
binding, and solvation patterns contribute to the entropy of ligand-binding.  Accordingly, if Arg, 
Erg, or Epg form receptor complexes that diverge substantially from those formed by TGFα and 
EGF, they should bind with a unique balance of enthalpy and entropy. 
We performed ITC titrations of Arg, Erg, and Epg into sEGFR-Fc (Fig. 15 A-C, Table 5).  
The measured parameters are summarized in Table 5, and presented graphically in Fig. 15D.  
We found that Erg exhibits an intermediate affinity for sEGFR-Fc, in between the high-affinity 
binders EGF and TGFα, and Arg/Epg, which both bind with lower affinity.  Broadly, each EGFR 
ligand we tested binds through an entropy-driven mechanism and exhibits highly disfavored 
enthalpic changes upon binding, in keeping with both EGF and TGFα and the VEGFR ligands.  
Furthermore, this pattern tracks with overall binding affinity; the low-affinity ligands Arg and Epg 
each exhibit an entropic driving force that is compromised by 6-9 kcal/mol compared to EGF and 
TGFα.  The enthalpic penalty of binding for Arg and Epg, however, is reduced by 4-6 kcal/mol 
compared to EGF and TGFα, mitigating the effect of a diminished entropic driving force.  The 
overall balance of entropic driving force and unfavorable enthalpies yields receptor-binding 
constants for Arg and Epg that are two orders of magnitude lower than those of EGF and TGFα.  
It must be noted, however, that the compensatory effects of enthalpy and entropy for these low- 
and high-affinity ligands argues that binding affinities alone would underestimate the divergence 
in the binding mode of Arg and Epg compared to EGF and TGFα.  In particular, the observed 
difference in ligand-binding entropy of 6-9 kcal/mol for low- and high-affinity ligands is consistent 
with a dramatic change in buried surface area upon ligand-binding(Olsson et al, 2008).  This 
entropic difference is consistent with a change of ~200-600 Å2 in the buried apolar surface area.  
EGF and TGFα each bury ~1500 Å2 total surface in published crystal structures.  In addition, the 
enthalpic discrepancy for low- versus high-affinity ligands is consistent with a difference of 3-4 
favorably hydrogen bonds.  Clearly, these thermodynamic data are consistent with major 
functional and structural differences in Arg- and Epg-EGFR complexes compared to EGF- and 
TGFα-EGFR complexes. 
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Figure 15: A-C: ITC titrations of the ligands Arg (A.), Erg (B.), and Epg (C.) into 25-28µM sEGFR-
Fc.  All titrations were fit to a single-site binding model, and the calculated KD and ΔH are 
specified on the plots. D. To visualize the enthalpic and entropic contributions of sEGFR-Fc 
binding for all the ligands tested at 25⁰C, ΔG, ΔH, and ΔS values were plotted for this interaction.  
For EGF and TGFα, these values have been extracted from the plots in Fig. 8A-B. 
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Table 5 
EGFR 
variant 
Ligand  KDLigand-binding, 
nM 
ΔSLigand-binding, 
cal/mol/K 
 ∆HLigand-binding, 
kcal/mol 
N 
sEGFR-Fc Arg  880 ±60 49.5  +6.5 ±0.1 1.06 
 
 
Erg 
Epg 
 170 ±19 
850 ±400 
67.8 
42.8 
 +11.0 ±0.1 
+4.5 ±0.3 
1.06 
1.21 
sEGFR-
FcY251A/R285S 
sEGFR501 
sEGFRWT 
Erg 
 
Epg 
Epg 
 2,740 ±300 
 
3,200 ±1,100 
39,000 ±20,000 
38.7 
 
19.5 
7.3 
 +4.1 ±0.1 
 
-1.7 ±0.1 
-3.9 ±2.8 
1.05 
 
1.03 
0.67 
 
Erg exhibits a unique pattern of ligand-binding enthalpy and entropy when compared to 
the high- and low-affinity ligands.  It is similar to the high-affinity ligands when comparing the 
enthalpy and entropy in isolation.  In that sense, one would predict it would mimic EGF and 
TGFα.  However, the thermodynamic changes (small as they may be) in Erg-binding compared to 
EGF and TGFα do not compensate, as observed for Arg and Epg; instead, they each contribute 
additively, to strongly disfavor binding of Erg to sEGFR-Fc.  Accordingly, the overall affinity of Erg 
is closer to that of the low-affinity ligands than the high-affinity ligands.  Thus, where Arg and Epg 
are likely to exhibit significant structural differences in the receptor complexes they induce, our 
data suggests Erg induces a more subtle difference, but a potentially important one nonetheless. 
Epigen- and Epiregulin-binding exhibit unique coupling to EGFR functional 
variants 
 
The striking differences in thermodynamics for high-, low-, and intermediate-affinity 
EGFR ligand-binding to sEGFR-Fc is consistent with important functional differences for the 
ligands.  These differences alone, however, do not provide functional insight.  To test whether 
distinct EGFR ligands may induce functionally unique receptor signaling complexes, we extended 
our study of ligand-binding thermodynamics using functionally-relevant EGFR variants. 
Given the importance of EGFR dimerization in receptor activation, we first sought to test 
how abrogation of the domain II dimerization interface affects ligand-binding.  Recall from the 
previous chapter that the high-affinity ligands exhibit equivalent overall binding affinity, but a 
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slightly increased (less favorable) ΔHligand-binding, upon mutation of the dimerization interface (Table 
1).  We performed ITC titrations of Epg, a low-affinity ligand, and Erg, an intermediate-affinity 
ligand that nonetheless mimics the thermodynamics of high-affinity ligands, into EGFR variants 
bearing either the wild-type dimerization interface or the Y251A/R285S double-mutation that 
abrogates receptor dimerization (Fig. 16 A-C).  Epg exhibits an equivalent affinity for sEGFR501 
regardless of the status of the receptor dimerization interface (Fig. 16C, red).  This same pattern 
holds for EGF and TGFα binding to sEGFRWT.  In other words, receptor-mediated dimerization 
and ligand-binding are very weakly-coupled for Epg, EGF, and TGFα.  In contrast, we found that 
Erg binding to sEGFR-Fc is highly sensitive to the receptor dimerization interface.  While sEGFR-
Fc binds Erg with a Kd of 170±19nM, sEGFRY251A/R285S-Fc exhibits a 17.1-fold weaker affinity for 
Erg (SD=1.1; result of 2 independent experiments; Fig. 16C, green).  These data argue that Erg 
binding is tightly-coupled to EGFR dimerization, in contrast to all other EGFR ligands tested. 
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Figure 16: ITC titrations of Erg and Epg into sEGFR variants, to examine their thermodynamic 
coupling to EGFR functions compared to EGF.  A: Erg titrated into 28µM sEGFR-Fc. B: Erg 
titrated into 17µM sEGFR-FcY251A/R285S.  C: The affinity dependence of EGFR ligands on domain 
II-mediated dimerization was compared by plotting the affinity ratios for matched EGFR proteins, 
with either wild-type or Y251A/R285S-mutated dimerization interfaces.  For EGF (blue), the 
comparison was made with 2 replicates of ITC-derived values for binding to sEGFRWT and 
sEGFRY251/R285S.  For TGFα (South), the comparison was made with representative ITC-derived 
values for binding to sEGFRWT and sEGFRY251/R285S.  For Epg (red), the comparison was made 
with representative ITC-derived values for binding to sEGFR501 and sEGFR501/Y251A/R285S.  For Erg 
(green), the comparison was made with 2 replicates of ITC-derived values for binding of sEGFR-
Fc and sEGFR-FcY251A/R285S.  Direct comparison for all ligands using the same EGFR proteins 
was not feasible due to technical constraints of ITC.  D-E: ITC titrations of Epg into 43µM 
sEGFR501 (D.) and 45µM sEGFRWT (E.).  F: The difference between ΔHligand-binding for sEGFRWT 
and sEGFR501, determined by ITC is plotted for EGF (blue) and Epg (red). 
 
Because coupling of dimerization and ligand-binding for Epg appeared similar to EGF 
and TGFα despite its vastly different thermodynamics, we sought to test the coupling of Epg 
binding to another EGFR functional variant that is independent of dimerization.  The sEGFR501 
variant is a truncated version of sEGFRWT that eliminates the tether interaction.  As described in 
the previous chapter, this variant dramatically increases the binding affinity for EGF and TGFα by 
eliminating an intramolecular interaction that stabilizes the ligand-free form of EGFR.  This has 
the effect of stabilizing EGF-binding by a favorable 3.9±0.3kcal/mol change in ΔHligand-binding 
compared to sEGFRWT(Fig. 16F, blue).  This effect is consistent with the minimal model 
presented in Fig. 3, as long as domain IV contributes minimally to receptor dimerization (which 
we know to be true for EGF)(Dawson, 2005).  In contrast, the effect on ΔHligand-binding for Epg 
binding to sEGFR501 versus sEGFRWT is strikingly different; Epg binding to sEGFR501 is actually 
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enthalpically dis-favored by 2.1±2.9kcal/mol compared to sEGFRWT (Fig. 16D-E).  The overall 
discrepancy in ΔΔH501>WT for Epg versus EGF is 6.0±3.2kcal/mol (Fig. 16F).  Technical 
challenges of the ITC experiment (due to low-affinity and a low ΔHligand-binding) preclude a precise 
determination of the Kd and ΔS for Epg binding to sEGFRWT.  Qualitatively, however, sEGFR501 
binds more tightly by about an order of magnitude (similar to EGF).  The considerable difference 
in ΔΔH501>WT for Epg strongly argues that the minimal structural model depicted in Fig. does not 
apply to Epg.  So what is the functional effect of Epg binding to EGFR?  Because Epg still signals 
via EGFR (presumably through inducing homodimers, Fig. 14D), and abrogation of the tether 
increases Epg affinity (implying that the tether interaction is broken upon ligand-binding, as for 
other EGFR ligands), the best explanation is that Epg-induced EGFR homodimers are uniquely 
dependent upon domain IV-mediated interactions. 
Conclusions 
 
It is widely assumed that all the EGFR ligands act through well-conserved allosteric 
effects to activate EGFR.  On the other hand, emerging evidence for ligand-specific effects on 
receptor conformation and signaling output begs for a mechanistic explanation(Hobbs, 2002; 
Scheck et al, 2012; Wilson et al, 2012a).  I report here the first attempts (to my knowledge) to 
broadly examine ligand-specific allosteric effects on EGFR.  Compared to the prototypical ligand 
EGF, we observed dramatic differences in the coupling of ligand-binding to dimerization (for Erg) 
and the domain II-domain IV tether interaction (for Epg).  In combination with the studies reported 
in Chapter 2, we can thus begin to build a more complete model of allosterically-induced EGFR 
signaling and make testable predictions of ligand-dependent receptor function.  
We suggested in Chapter 2 that the preference of EGF for ErbB2:EGFR heterodimers (Li 
et al, 2012) may explain the weak coupling of EGF binding to EGFR homodimerization.  In order 
to adaptively maintain a preference for ErbB2:EGFR heterodimers, EGF must adaptively maintain 
an affinity for EGFR monomers that is at least comparable to that for EGFR homodimers.  
Otherwise, EGF-induced EGFR homodimers would be the predominant complex formed when 
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ErbB2 and EGFR are both present.  This sort of weak coupling between ligand-binding and 
homodimerization is also observed for the ligands TGFα and Epg.  In contrast, the binding of Erg 
is tightly coupled to domain II-mediated EGFR dimerization.  This observation suggests that Erg 
may be adapted to signal preferentially through EGFR homodimers, rather than through 
ErbB2:EGFR heterodimers.  In agreement with this notion, it has been reported that Erg induces 
less ErbB2 transactivation compared to EGF when applied to cells overexpressing 
ErbB2(Komurasaki et al, 1997).  Other reports have also shown Erg binds to and activates ErbB4 
as well, and that Erg activation is dependent upon the presence of other ErbB receptors – 
consistent with ligand-specific preferences for certain ErbB signaling complexes(Jones, 1999; 
Riese et al, 1998).  One important caveat for these studies is that they have all used bacterially-
derived Erg proteins; bacterially-derived Erg binds EGFR with a ~10-fold lower affinity than the 
insect-derived Erg I have produced, and it lacks a beta-strand in the C-terminal region that is 
conserved in EGF, TGFα, and HB-EGF(Jones, 1999; Louie et al, 1997; Sato et al, 2003).  Given 
these concerns, it will be important to re-evaluate patterns of Erg-induced ErbB activation with the 
insect cell-derived Erg we have created.  Beyond simply inducing EGFR homodimers 
preferentially over ErbB2:EGFR heterodimers, it is also possible that Erg induces a distinct EGFR 
homodimer with unique signaling properties.  The fact that EGFR homodimerization ‘feeds back’ 
to stabilize Erg-binding, but fails to stabilize EGF-, TGFα-, and Epg-binding, is indeed suggestive 
that Erg induces a unique EGFR homodimer conformation.  Further experiments are needed to 
determine whether the Erg-EGFR homodimer complex exhibits unique signaling properties. 
The ligand Epg appears to be insensitive to the EGFR domain II dimerization interface, 
like EGF and TGFα (and in contrast to Erg).  On the other hand, it is highly sensitive to the 
presence of domain IV in a unique way, typified by a less-favorable ΔHligand-binding for sEGFR501 
compared to sEGFRWT.  One possible explanation is that Epg induces an EGFR homodimer that 
uniquely exploits the domain IV dimerization interface.  Prior work has suggested that the domain 
IV dimerization interface is dispensable for EGF-induced EGFR homodimerization (Dawson, 
2005), but this may not be the case for Epg-induced EGFR dimerization.  Domain IV-mediated 
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dimerization has been observed crystallographically, and it has been reported to play a key role in 
translating ligand-binding into receptor kinase activity (Arkhipov et al, 2013; Lu et al, 2010; Moriki 
et al, 2001).  Accordingly, any ligand-specific difference in the domain IV dimeric interface could 
play an important role in modulating the EGFR signaling response in a ligand-specific way. 
The observations we report here on the thermodynamics of EGFR ligand-binding will 
require further experiments to bridge the gap from biochemical observations to functional 
consequences in cells.  Regardless, the striking and unexpected diversity in the thermodynamics 
of ligand-binding and in ligand sensitivity to receptor variants clearly argues that ligand-specific 
allosteric effects on EGFR do exist.  This notion has been hinted at before, but our development 
of new reagents has allowed us to test this idea and begin to speculate about novel, ligand-
specific functions(Wilson et al, 2009).  Insight into the precise nature of ligand-specific signaling 
differences should allow the development of more effective ErbB-targeted therapeutics.  For 
example, specific stimulation of ErbB2:ErbB4 heterodimers might abrogate trastuzumab-induced 
cardiomyopathy, and better functional mimics of Arg, Epg, and Erg might aid in vitro maturation 
(Richani et al) protocols for fertility treatments – where EGF alone is less effective than these 
ligands(Guglin et al, 2008; Richani et al, 2014). 
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It will be useful to go back to the simplest possible concept of RTKs as transmembrane signaling 
modules when considering the data I have presented here.  To date, RTKs are largely assumed 
to represent a discrete switch: they are either active or inactive, with no grey area in between.  
This notion contrasts with our understanding of another broad family of transmembrane signaling 
modules, the G-protein coupled receptors, or GPCRs.  It has long been recognized that distinct 
GPCR ligands may induce discrete functional outcomes, and that the origin of these differences 
can be autonomous to the ligand:GPCR complex itself(Stephenson, 1997).  Only more recently 
has the cellular context of a distinct ligand:GPCR signal come to the fore; it is now clear that a 
single GPCR ligand, acting through a single receptor, can simultaneously function as both an 
agonist and an antagonist(Urban et al, 2007a).  The cellular interpretation of a GPCR ligand as 
agonist or antagonist can depend primarily on which specific output is measured(Urban et al, 
2007b).  For our purposes, this is a double-edged sword.  On one hand, it is satisfying and 
compelling to uncover hidden complexity in the signaling response of a single transmembrane 
receptor.  On the other hand, this knowledge argues against the broad utility of simple two-state 
models of receptor activity, and demands a much more complex model to understand (and to 
therapeutically exploit) all the known transmembrane receptors. 
The conceptual parallels between GPCRs and RTKs here are striking.  Like GPCRs, single RTKs 
can activate a multitude of signaling pathways simultaneously (Alroy & Yarden, 1997; Jones et al, 
2006).  Like GPCRs, RTK ligands have shown a variety of different thermodynamic mechanisms 
for binding to the same receptor (Borea et al, 1998; Brozzo et al, 2012).  For GPCRs, the 
thermodynamics of ligand-binding has in some cases been highly correlated with the functional 
activity of the ligand(Borea et al, 1998).  Such a ligand-dependent functional link between the 
thermodynamic mechanism of ligand-binding and the functional receptor output has not yet been 
established for RTKs.  However, it has only very recently been recognized that RTK output may 
in fact be ligand-dependent(Wilson et al, 2009).  The data I have presented above, not only 
showing that EGFR ligands bind through different thermodynamic mechanisms, but also that 
these ligands exhibit unique linkage to EGFR functional variants, argues quite clearly that 
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receptor-autonomous, ligand-dependent signaling outputs are feasible biophysically.  In analogy 
to data I have presented for EGFR, others recently showed that the VEGFR-2 ligands VEGF-A, 
VEGF-C, and VEGF-E bind receptor with unique thermodynamics, and they each exhibit unique 
thermodynamic linkage to deletion of the membrane-proximal Ig domains D4-D7, which are 
required for VEGFR signaling(Brozzo et al, 2012).  In combination, these data begin to suggest 
that receptor-autonomous, ligand-specific signaling responses may indeed be a general and 
unappreciated feature of RTK signaling.  If this is true, it would have broad implications for 
understanding RTK function and for drug design.   
The challenge in going forward will be to carefully test the biological relevance of the biophysical 
ligand differences we have observed.  Three primary techniques will be exploited in the future to 
test the idea that EGFR ligands can induce unique responses by generating unique receptor 
complexes.  First, cell-based assays in which all four ErbB receptors are combinatorially 
expressed will be stimulated with the ligands EGF, TGFα, Arg, Erg, and Epg.  Because ErbB 
receptors signal by phosphorylating specific tyrosine residues on the receptor C-tail, we will 
measure receptor output at this level by using well-established, phosphorylation-site-specific 
antibodies for western blotting(Yang et al, 2006).  This approach has an advantage over general 
phosphotyrosine detection, because it will be far more sensitive to signaling differences(Kim et al, 
2012).  Prior studies have suggested that Arg results in less phosphorylation at Y1045 of EGFR 
compared to EGF(Roepstorff et al, 2009; Willmarth et al, 2009).  Based on the strong linkage I 
have observed between Erg binding and EGFR homodimerization, I hypothesize that Erg will 
show a relatively low level of ErbB2 phosphorylation compared to EGF when each ligand is 
applied to cells expressing EGFR and ErbB2, owing to a preference for EGFR homodimers. 
Another approach will employ near-full length EGF receptor, which contains the ECR, the 
transmembrane domain, and the intracellular kinase domain, but no C-terminal tail.  This protein 
has recently been purified in micelles and lipid nanodiscs, and shown to recapitulate EGF-
dependent kinase activity(Mi et al, 2011; Qiu et al, 2009).  I will add the different purified ligands 
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to this form of the receptor and perform kinase activity assays, to determine the linkage between 
ligand-binding and kinase activity for each ligand.  Based on the observation that TGFα induces a 
unique conformation in the intracellular juxtamembrane region, which regulates kinase activity, I 
predict that I will observe different patterns of kinase activation for the different ligands I 
test(Scheck et al, 2012). 
Finally, I will attempt to determine a high-resolution crystal structure of Arg, Erg, and Epg bound 
to different variants of EGFR, as well EGF bound to (mutated) monomeric EGFR.  Preliminary 
crystals of an EGF:sEGFRY251A/R285S variant have already been obtained.  Based on the 
thermodynamics of ligand-binding, I predict that Arg, Erg, and Epg will exhibit slightly different 
ligand:receptor interactions compared to EGF and TGFα.  Furthermore, I predict that Erg will 
induce a unique EGFR homodimer interface.  Based on the poor thermodynamic linkage between 
EGFR homodimerization and EGF binding, I predict that an EGF:sEGFRY251A/R285S complex will 
exhibit a domain II dimerization-arm conformation that is different from the conformation in the 
EGFR homodimer.  Crystal structures of these complexes, should they differ from those observed 
for EGF- and TGFα-induced EGFR homodimers, will be used to design mutations to probe the 
functional implications of the observed conformations. 
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Reagents 
EGF and TGFα were purchased from Millipore and R&D systems.  Both sources gave identical 
results in ITC binding assays.  All receptor proteins were expressed in Sf-9 cells utilizing a 
baculovirus system using the pFastbac (pFb) plasmid (Invitrogen).  Construction of the tether-
compromised and monomeric-EGFR variants has been previously described(Dawson, 2005).  
Glioblastoma mutations were introduced via Quikchange PCR.  sEGFR-Fc was constructed by 
mutating pFb-sEGFRWT to create an FseI restriction site at the c-terminus.  cDNA encoding the 
Fc domain from human IgG1 (IMAGE clone 4575935) was purchased from Open Biosystems, 
and was used as a PCR template to create a fragment containing the Fc domain coding region 
flanked by FseI and NotI sites at the 5’ and 3’ ends, respectively.  This fragment was cloned into 
the pFb-sEGFRWT plasmid containing an FseI restriction site, yielding a plasmid coding for 
residues 1-645 of the EGFR protein, followed by ‘AG’ (introduced by the FseI site), and further 
followed by the 231 residue Fc domain, with a hexa-His tag at the C-terminus.  sEGFR-ZIP was 
constructed by first amplifying a fragment encoding the 33-residue coiled-coil domain from yeast 
GCN4 by a series of 4 PCR reactions, each extending the length of the fragment at the 3’ end.  
This fragment also contained 20 nucleotides at the 5’ end that were complementary to the C-
terminus of sEGFR, as well as a hexa-His tag and NotI site at the 3’ end.  This fragment was 
used as a primer to amplify (from a pFb-sEGFRWT template) a fragment encoding sEGFR 
followed by the 33-residue coiled-coil domain and a His tag into pFb. 
Protein purification 
All EGFR receptor proteins were purified by the same procedure.  Briefly, 4 days post-infection, 
conditioned media were concentrated to ~1l and diafiltered against 4l of buffer containing 20mM 
HEPES, pH 8.0, and 150mM NaCl (binding buffer).  Diafiltered media was passed over NiNTA-
agarose, and proteins were eluted by increasing concentrations of imidazole in binding buffer.  
Imidazole fractions containing receptor were dialyzed or buffer-exchanged via serial 
concentration into cation exchange buffer (20mM MES, pH 6.0, and 50 mM NaCl) and purified via 
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cation-exchange chromatography, followed by size-exclusion chromatography on a Superose 6 
column in binding buffer. 
Ligands were purified exactly as described for receptors, with a few exceptions.  For Erg and 
Epg, hygromycin-selected stably-transfected S2 cell lines were created with a pMT vector 
encoding the expression cassette described in Fig. 14.  Arg was produced using the pFastbac a 
baculovirus system as described for sEGFR above.  Erg and Epg expression in S2 cells was 
induced by adding 500µM CuSO4 to the culture medium, and media was harvested and 
diafiltered after 4 days of expression.  Arg, Erg, and Epg were sequentially purified by NiNTA-
agarose affinity chromatography, cation-exchange chromatography on an SO3 column, and size-
exclusion chromatography on a Superose 12 column.  For Erg, the buffer was adjusted via 
dialysis to 20mM HEPES, pH 7.5, and 70mM NaCl for the cation exchange step, while Arg and 
Epg were bound to the SO3 column in 20mM MES, pH 6.0, and 50mM NaCl.  For Erg and Epg, a 
final purification step was added in which gel filtration fractions were passed first through a 
50kDa-MWCO protein concentrator, and then through a 30kDa-MWCO protein concentrator.  In 
each concentration step, approximately half the ligand was retained in the concentrator and half 
flowed through, while >90% of the contaminant proteins was retained.  This step was important 
for accurate protein concentration determination by 280nm absorbance measurements, as the 
contaminant proteins absorbed strongly at 280nm. 
Isothermal Titration Calorimetry 
Receptor and ligand proteins were dialyzed overnight into ITC buffer, containing 20 mM HEPES, 
pH 8.0, 150 mM NaCl, and 3.4 mM EDTA.  Receptor concentration in the cell was 10 µM unless 
otherwise specified, and ligand was injected at concentrations of 60-120 µM.  All protein 
concentrations were determined by measuring absorbance of purified protein at 280nm and 
dividing by an extinction coefficient that was predicted from primary amino acid sequence.  
Generally, 20 ligand injections of 2 µL were performed for each receptor, and data from the first 
injection were always discarded to eliminate syringe leakage artifacts.  For Erg and Epg titrations, 
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13 injections of 3 µL were performed to increase the signal-to-noise ratio for each injection.  
Ligand titrations into receptor-free ITC buffer were performed to determine the heat of ligand 
dilution when receptor was not fully saturated in a given experiment, and these heats were 
subtracted out from the receptor titration data.  All experiments were performed at 25⁰ C (except 
for those described in Fig. 9) in a Microcal ITC200 instrument.  Data were fit to a single-site 
binding model in the Origin software package.  All titrations were performed independently at 
least three times, and representative titrations are shown. 
Fluorescence Anisotropy-based binding assays 
EGF was labeled with Alexa-488 utilizing a TFP ester to label primary amines, according to the 
protocol provided with the Alexa Fluor 488 Protein Labeling Kit from Molecular Probes (Eugene, 
OR).  After labeling, EGF was purified away from free dye by size-exclusion chromatography on a 
Superdex Peptide column in buffer containing 20mM HEPES, pH 8.0, plus 150 mM NaCl.  
Labeling efficiency was calculated by measuring the absorbance of purified, labeled EGF at both 
280 nm and 490 nm, and assuming an extinction coefficient of 18,825 cm-1M-1 at 280 nm (as 
predicted from the primary sequence of EGF) and 71,000 at 490 nm (for the Alexa-488 dye).   10 
nM (for sEGFR-Fc and sEGFR-Zip) or 60 nM (for sEGFRWT) EGF488 was incubated with varied 
amounts of receptor protein for 30 minutes at RT in buffer containing 20mM HEPES, pH 8.0, and 
150mM NaCl.  Fluorescence polarization (FP) measurements were taken on a Beacon instrument 
at 20º C.  FP values were converted to anisotropy, and binding curves were derived by assuming 
that the maximal anisotropy response corresponded to [EGFfree]=0, while the anisotropy in the 
absence of receptor corresponded to [EGFfree]=[EGFtotal].  These curves were fit to binding 
models using the Graphpad Prism software.  sEGFR-Fc and sEGFRWT binding data were fit to 
simple single-site binding models, while sEGFR-Zip binding data were fit to a Hill model with a Hill 
coefficient of ~1.9, presumably reflecting the presence of sEGFR-Zip monomers at very low 
receptor concentrations. 
Electron microscopy 
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Receptor samples at a concentration of 2 µg/ml in binding buffer were applied to glow-discharged 
carbon grids and stained with 0.75% uranyl formate.  Images were collected on a Tecnai T12 
microscope at 67,000x magnification and operating at 120 keV.  For the EGF:sEGFR-Fc 
complex, 755 individual particles, manually picked from 150 images using the EMAN software 
package (Ludtke et al, 1999), were grouped into 10 classes by a reference-free alignment 
procedure in Spider (Frank et al, 1996).  For the sEGFR-Fc protein alone, 2,566 particles from 
673 images were grouped into 20 classes by the same reference-free alignment procedure. 
Small-angle x-ray scattering 
SAXS protein samples were prepared at concentrations of 10-20 µM in binding buffer, and 40 
minute exposures at 4ºC were performed on a Rigaku SMAX3000 instrument, using a Rigaku 
007HF rotating anode source and a Rigaku 300mm wire grid ASM DTR 200 detector.  Scattering 
data were radially-averaged and reduced to two-dimensional plots using the SAXSgui software, 
and intensity data from buffer exposures was then subtracted out.  Radii of gyration were 
determined by Guinier plots using the Primus software package.  The maximal interatomic 
distance (Dmax) was obtained by examining p(r) curves generated by the Gnome software 
package.  Briefly, for each scattering dataset, p(r) curves were calculated for a range of Dmax 
from 100 to 250 Å, in 5Å increments.  Dmax was determined by finding the value that gave the 
best fit to the experimental scattering data. 
Analytical ultracentrifugation 
Receptor protein samples at a concentration of either 10 µM (sEGFRWT) or 5 µM (sEGFRR84K, 
sEGFRA265V, and sEGFRA265D) were loaded into 6-hole sample cells for sedimentation equilibrium 
analytical ultracentrifugation analysis with a Beckman XL-A instrument at rotor speeds of 9,000 
and 12,000 rpm.  For conditions with TGFα, the ligand was present in a 1.2-fold excess over 
receptor protein.  Data were analyzed using Sedfit and Sedphat, as well as simple log plots of 
absorbance intensity data, as previously described (Ferguson, 2000).  For log plots, a constant 
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value was added to each data point within a single sample to align the log plots to the origin; this 
procedure does not affect the fit, which depends only on the slope of the line. 
Cell stimulation 
Cell lines (either A431 or MDA-MB-468) were cultured in DMEM containing 10%FBS, and 
100u/ml of penicillin and streptomycin.  Cells were split into 10mm culture dishes at a density of 
~50%.  Once cells reached 80-90% confluence, they were switched to serum-free media and 
incubated overnight.  Cells were then cooled on ice for 30 minutes and washed with stimulation 
buffer (cold DMEM containing 3% BSA).  Cells were stimulated by adding 5ml of ligand, at the 
specified concentration, in stimulation buffer.  As a positive control, carrier-free EGF from 
Millipore was used.  After 10 minutes, the cells were immediately rinsed with stimulation buffer, 
and harvested in 1mL RIPA buffer (containing PMSF, Leupeptin, Aprotinin, NaF, Vanadate, and 
Molybdate to inhibit proteases and phosphatases)  using a cell scraper.  Cells were lysed for 30 
minutes at 4⁰C on a Nutator.  Cell lysates were clarified by spinning at 15,000 RPM at 4⁰C in a 
benchtop centrifuge, and the supernatant was used for analysis by western blotting.  
Alternatively, 500 µl was incubated for 1 hour with 50 µl of Concanavalin-A 4B sepharose in RIPA 
(GE) at 4⁰C to enrich for glycosylated proteins.  Proteins were then eluted by boiling in reducing 
PAGE sample buffer containing 1mM EDTA for analysis by western blotting. 
Western blotting 
Blotting samples were run on a 7.5% PAGE gel and transferred to nitrocellulose membranes.  
Membranes were blocked for 1 hour at 4⁰C with PBS+3% BSA.  PY20 antibody (Jaiswal et al) 
was added at 1µg/ml, and incubated overnight at 4⁰C.  Membrane was washed 3x in 5ml of PBS, 
and HRP-linked anti-Mouse antibody was added and incubated for 1 hour at room temperature.  
The blots were imaged using the SuperSignal ECL kit (Pierce). 
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